{"gene":"COL4A1","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":2005,"finding":"A semidominant missense mutation in Col4a1 (in-frame deletion of exon 40) inhibits secretion of both mutant and normal type IV collagen, causing focal disruptions of vascular basement membranes and perinatal cerebral hemorrhage/porencephaly in mice; surgical delivery alleviated birth-associated hemorrhage, demonstrating that environmental trauma conspires with the mutation.","method":"Mouse genetics (semidominant mutant characterization), cellular secretion assay, histology of vascular basement membranes, surgical intervention experiment","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (genetic, cellular biosynthesis assay, surgical rescue), replicated across two papers (PMID:15905400, PMID:16598045)","pmids":["15905400","16598045"],"is_preprint":false},{"year":2005,"finding":"Dominant missense mutations affecting conserved glycine residues in the Gly-X-Y collagen repeat of Col4a1 cause dominant-negative effects on expression and function of the major collagen IV isoform α1(IV), leading to basement membrane defects in the eye (Axenfeld-Rieger-like anterior segment dysgenesis, glaucoma) and kidney (glomerulopathy); a milder allele with a Yaa-residue mutation produces a less severe phenotype, establishing allele-severity correlations.","method":"ENU mutagenesis allelic series in mice, histology, electron microscopy of basement membranes, slit-lamp and ophthalmological phenotyping","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — allelic series with multiple orthogonal methods; replicated in subsequent studies","pmids":["16159887"],"is_preprint":false},{"year":2007,"finding":"A Col4a1 missense mutation causes non-secretion of mutant COL4A1 proteins, which accumulate intracellularly, induces endoplasmic reticulum (ER) stress, and leads to anterior segment dysgenesis and optic nerve hypoplasia; the overall phenotypic consequence depends on genetic context, with a single dominant modifier locus capable of rescuing both ASD and optic nerve hypoplasia.","method":"Mouse genetics, protein secretion assay, ER stress markers, genetic modifier mapping","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (biosynthesis assay, ER stress markers, genetic modifier screen) in one study","pmids":["17317786"],"is_preprint":false},{"year":2010,"finding":"Col4a1 missense mutation (Col4a1+/Raw) in mice causes focal endothelial detachment from the media, impaired collagen IV deposition in vascular basement membranes, activation of the unfolded protein response, reduced basal nitric oxide synthase (NOS) activity, age-dependent hypersensitivity to acetylcholine abolished by NOS inhibition, and reduced red blood cell volume causing hypotension; together these establish that COL4A1 mutations produce complex vascular dysfunction through both structural basement membrane defects and ER stress.","method":"Vascular function assays (vasoconstriction/vasodilation), NOS inhibitor pharmacology, collagen IV immunostaining/electron microscopy, blood pressure measurement, red blood cell counting, unfolded protein response markers","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal functional and molecular methods in a single study with clear mechanistic readouts","pmids":["20056676"],"is_preprint":false},{"year":2011,"finding":"COL4A2 mutations (identified in ICH patients) cause intracellular retention of both COL4A1 and COL4A2 within the endoplasmic reticulum at the expense of their secretion, trigger ER stress and activate the unfolded protein response; Col4a2 mutant mice have completely penetrant intracerebral hemorrhage, establishing that COL4A1 and COL4A2 form heterotrimers and that mutations in either chain impair secretion of the entire heterotrimer.","method":"Cellular secretion assay, ER retention immunostaining, unfolded protein response markers, Col4a2 mutant mouse phenotyping, sequencing of ICH patients","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal cellular assays, mouse model, UPR markers; multiple orthogonal methods","pmids":["22209247"],"is_preprint":false},{"year":2011,"finding":"Heterozygous Col4a1 mutations in mice cause ocular dysgenesis, neuronal localization defects, and myopathy characteristic of MEB/WWS; at least one mutation interferes with secretion of mutant proteins causing intracellular accumulation; dystroglycan expression and post-translational modification are unaltered in Col4a1 mutant mice, establishing that COL4A1 mutations represent a pathogenic mechanism distinct from dystroglycan glycosylation defects.","method":"Histology, molecular and biochemical approaches (secretion assay, dystroglycan immunoblot/glycosylation analysis), patient mutation identification","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (biosynthesis assay, histology, negative dystroglycan result as mechanistic discriminator)","pmids":["21625620"],"is_preprint":false},{"year":2012,"finding":"Two novel COL4A1 mutations (a frameshift c.2085del and a splice-site mutation c.2194-1G>A) cause nonsense-mediated decay (NMD) of mutant COL4A1 mRNA and a clear reduction in COL4A1 protein, establishing haploinsufficiency as a distinct pathogenic mechanism (in addition to the dominant-negative mechanism seen with missense mutations) for COL4A1-related cerebral small vessel disease; capillary basement membrane thickening was also documented in patient skin.","method":"NMD assay in patient fibroblasts, COL4A1 protein quantification, RT-PCR splice analysis, skin electron microscopy","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — NMD demonstrated in patient-derived cells with multiple molecular readouts in one study","pmids":["23065703"],"is_preprint":false},{"year":2012,"finding":"Putative COL4A1 mutations found in sporadic ICH patients (P352L and R538G), but not variants from ICH-free controls, impair COL4A1 secretion in a cellular assay, demonstrating a shared biosynthetic mechanism across an allelic series causing both familial and sporadic cerebrovascular disease.","method":"COL4A1 biosynthesis/secretion assay in cell culture, sequencing of sporadic ICH patients vs. controls","journal":"Annals of neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — cellular secretion assay, single lab, two variants tested","pmids":["22522439"],"is_preprint":false},{"year":2013,"finding":"COL4A1 and COL4A2 mutations cause increased intracellular and decreased extracellular protein for most alleles, but allelic heterogeneity produces distinct biosynthetic signatures for some mutations; reduced temperature or 4-phenylbutyrate treatment ameliorated biosynthetic defects in primary cell lines from mutant mice, confirming ER folding/secretion as a targetable mechanism.","method":"Biosynthesis assay (intracellular/extracellular protein quantification) in primary cells from allelic series mutant mice, pharmacological rescue with 4-PBA and reduced temperature","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple alleles, multiple methods, pharmacological rescue; one rigorous study","pmids":["24203695"],"is_preprint":false},{"year":2007,"finding":"All six COL4A1 mutations associated with HANAC syndrome localize within the CB3[IV] fragment of the collagenous domain, which encompasses major integrin-binding sites, suggesting that abnormal cell–type IV collagen interactions (via integrin binding sites) underlie the systemic vascular defects in HANAC.","method":"Clinical and genetic characterization, mutation mapping to functional domain (CB3[IV] integrin-binding region), sequencing of affected families","journal":"The New England journal of medicine","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — domain mapping across multiple families establishes genotype-structure correlation, but direct integrin-binding functional assay not reported in abstract","pmids":["18160688"],"is_preprint":false},{"year":2015,"finding":"The HANAC Col4a1 p.Gly498Val mutation in knock-in mice causes delayed glomerulogenesis and podocyte differentiation, leading to neonatal albuminuria; in adult mice, Bowman's capsule abnormalities are associated with metalloproteinase induction, activation of parietal epithelial cells (expressing CD44, α-SMA, ILK, DDR1), inflammatory infiltrates, and glomerular cyst development; homozygous mice additionally show dysmorphic papillae and urinary concentration defects, revealing a developmental role for the α1α1α2(IV) heterotrimer in the embryonic glomerular basement membrane.","method":"Knock-in mouse model, histology/immunostaining, metalloproteinase expression analysis, functional renal assays (albuminuria, hematuria, urinary concentration)","journal":"Journal of the American Society of Nephrology","confidence":"High","confidence_rationale":"Tier 2 / Strong — knock-in mouse with multiple orthogonal molecular and functional readouts in one study","pmids":["26260163"],"is_preprint":false},{"year":2016,"finding":"ER stress and basement membrane defects both contribute to Col4a1 renal disease in mice: glomerular/Bowman's capsule structural BM defects cause glomerular filtration impairment, while medullary atrophy is associated with chronic ER stress without tubular basement membrane defects, demonstrating cell-type-dependent molecular mechanisms; impaired tubular sodium reabsorption despite elevated aldosterone indicates BM modulation of tubular aldosterone response.","method":"Col4a1 mutant mouse phenotyping, ER stress marker analysis, electron microscopy of BMs, functional renal assays (proteinuria, aquaporin 2 expression, aldosterone levels)","journal":"Disease models & mechanisms","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (EM, biochemical, physiological) demonstrating tissue-specific mechanistic heterogeneity","pmids":["26839400"],"is_preprint":false},{"year":2016,"finding":"Disruption of a miR-29 binding site in the 3'UTR of COL4A1 causes upregulation of COL4A1 expression, establishing that gain-of-function COL4A1 overexpression (not just loss-of-function missense mutations) causes a severe ischemic cerebral small vessel disease (PADMAL); demonstrated by luciferase reporter assays and RT-qPCR in patient fibroblasts.","method":"Luciferase reporter assay, RT-qPCR of patient fibroblasts, linkage analysis, mutation screening of cSVD cohort","journal":"Annals of neurology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — luciferase and RT-qPCR in patient-derived cells with cosegregation; establishes novel gain-of-expression mechanism","pmids":["27666438"],"is_preprint":false},{"year":2017,"finding":"In a HANAC Col4a1 G498V knock-in mouse model, skeletal muscle myopathy is primarily driven by endothelial cell defects in muscle capillaries: endothelial cells accumulate mutant α1α1α2(IV) intracellularly, show ER cisternae dilation, upregulate ER stress markers, and undergo excess apoptosis; reduced extracellular secretion of the mutant heterotrimer contributes to abnormal muscle BMs.","method":"Knock-in mouse histology/ultrastructure, immunostaining (ER stress markers, apoptosis), collagen IV secretion analysis, serum creatine kinase measurement","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — knock-in model with ultrastructural, molecular and functional readouts establishing primary vascular/endothelial mechanism","pmids":["28056338"],"is_preprint":false},{"year":2017,"finding":"Conditional Col4a1 mutation expressed selectively in lens cells (but not in neural crest cells alone, nor vascular endothelial cells alone on unsensitized background) causes cataracts, mild ASD, optic nerve hypoplasia, and age-related IOP dysregulation and optic nerve damage; ubiquitous expression at distinct developmental stages indicates pathogenesis occurs before E12.5 in mice.","method":"Conditional (cell-type-specific and temporally controlled) Col4a1 mutation in mice, slit-lamp biomicroscopy, OCT, IOP measurement, optic nerve histology","journal":"Disease models & mechanisms","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional genetics with multiple cell-type-specific alleles and functional ocular readouts","pmids":["28237965"],"is_preprint":false},{"year":2016,"finding":"Col4a1 mutations in mice cause progressive retinopathy driven by primary vascular defects: conditional Col4a1 mutation in vascular cells reproduces the retinal pathology (serous chorioretinopathy, hemorrhages, pathogenic angiogenesis); focal Müller cell activation and increased expression of pro-angiogenic factors were detected in Col4a1 mutant retinas.","method":"Conditional vascular-specific Col4a1 mutation, fluorescein angiography, funduscopy, OCT, electroretinography, ultrastructural analysis, Müller cell and angiogenic factor immunostaining","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional genetics with multiple functional and molecular readouts establishing primary vascular mechanism","pmids":["26813606"],"is_preprint":false},{"year":2019,"finding":"Col4a1 mutant mice develop progressive neuromuscular pathology with mechanistic heterogeneity across tissues: independent muscular, neural, and vascular insults all contribute to neuromyopathy; a therapeutic strategy promoting [α1(IV)]2α2(IV) secretion can either ameliorate or exacerbate myopathy depending on the specific mutation, demonstrating mutation-dependent therapeutic responses.","method":"Col4a1 mutant mouse characterization, histology, molecular pathway analysis, pharmacological secretion-promoting treatment with phenotypic readout","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods, mutation-dependent therapeutic outcome establishes allelic mechanistic heterogeneity","pmids":["31051113"],"is_preprint":false},{"year":2019,"finding":"4-Phenylbutyric acid (PBA) treatment of Col4a1 mutant mice reduces ER stress, increases collagen IV incorporation into basement membranes, and reduces adult intracerebral hemorrhage in both preventive and therapeutic settings; however, PBA does not improve eye or kidney defects, and persistence of structural BM defects indicates that BM matrix integrity is not fully restored—establishing tissue-specific outcomes of targeting ER stress.","method":"Oral PBA treatment of mutant mice (preventive and therapeutic), ICH quantification, ER stress markers, collagen IV BM incorporation assay, mechanical stress testing of BM, kidney/eye phenotyping","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacological intervention with multiple orthogonal outcome measures and tissue-specific resolution","pmids":["30351356"],"is_preprint":false},{"year":2018,"finding":"In Col4a1 p.G498V mutant mice, microhaemorrhages are associated with transient generalized blood-brain barrier permeability at the capillary level, while macrohaemorrhages originate from deep brain arteries with focal loss of smooth muscle cells via apoptosis-mediated degeneration; the same smooth muscle cell loss occurs in retinal arteries, and retinal arterial lesion load correlates strongly with macrohaemorrhage burden.","method":"Histology, immunohistochemistry, electron microscopy of brain/retinal vessels, blood-brain barrier permeability assay, time-course analysis, in-parallel retinal and brain hemorrhage quantification","journal":"The Journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods identifying two mechanistically distinct hemorrhage processes","pmids":["29266233"],"is_preprint":false},{"year":2021,"finding":"A genetic modifier screen in Col4a1 mutant mice identified a single locus (MoGS1) on Chromosome 1 containing Fn1 (fibronectin 1) that suppresses ocular anterior segment dysgenesis and myopathy (but not ICH) in Col4a1 mutants; the MoGS1 locus increases Fn1 expression and is associated with increased integrin-linked kinase levels and focal adhesion kinase phosphorylation, implicating integrin signaling in ocular and muscular COL4A1 pathology.","method":"Genetic modifier screen, QTL mapping, molecular expression analysis (Fn1, ILK, FAK phosphorylation), phenotypic scoring of ASD and myopathy","journal":"Disease models & mechanisms","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic modifier locus with molecular correlates, single lab","pmids":["34424299"],"is_preprint":false},{"year":2022,"finding":"TGFβ signaling is elevated in anterior segments from Col4a1 mutant mice; genetically reducing TGFβ signaling partially prevents ASD; TGFβ1 and TGFβ2 play distinct roles in ocular defects; pharmacologically promoting type IV collagen secretion or reducing TGFβ signaling ameliorates ocular pathology.","method":"Histology, TGFβ signaling pathway analysis, genetic reduction of TGFβ (epistasis), pharmacological treatment (secretion promoter, TGFβ inhibitor), slit-lamp phenotyping","journal":"Matrix biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis plus pharmacological rescue with multiple readouts establishing causal TGFβ pathway involvement","pmids":["35525525"],"is_preprint":false},{"year":2023,"finding":"Col4a1 mutations impair sarcoplasmic reticulum (SR) Ca2+ signaling in vascular smooth muscle cells, blunting pressure-induced membrane depolarization and causing loss of myogenic vasoconstriction; this impairs autoregulation of cerebral blood flow and contributes to age-related ICH. Specifically, SR Ca2+ disruption impairs Ca2+-dependent activation of BK and TRPM4 channels. Treatment with 4-phenylbutyrate restored SR Ca2+ signaling, maintained BK and TRPM4 channel activity, preserved myogenic tone, and reduced ICH.","method":"Electrophysiology (patch clamp of SMCs), Ca2+ imaging, BK/TRPM4 channel activity assays, myogenic tone measurement, pharmacological treatment (4-PBA), ICH quantification","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro electrophysiology with pharmacological rescue and multiple orthogonal mechanistic readouts in one rigorous study","pmids":["37963192"],"is_preprint":false},{"year":2023,"finding":"In a human iPSC co-culture model of COL4A1/A2 SVD, mutations induce apoptosis, migration defects, ECM remodeling, and high matrix metalloproteinase (MMP) expression in mural cells; these mural cell defects impair endothelial cell tight junctions through paracrine actions; MMP inhibition partially rescues ECM abnormalities and mural cell phenotypic changes.","method":"Human iPSC-derived mural/endothelial cell co-culture, transcriptomics, ECM analysis, MMP expression assay, pharmacological MMP inhibition, tight junction assessment","journal":"Stem cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — human iPSC model with pharmacological rescue, multiple orthogonal methods","pmids":["37977146"],"is_preprint":false},{"year":2023,"finding":"Fluorescently tagged COL4A1 (mTurquoise2-Col4a1 knock-in mouse) shows by FRAP that basement membrane collagen IV is extremely stable even during rapid epidermal growth; live imaging demonstrates that dividing basal cells deform but remain attached to the BM rather than losing adhesion, establishing the BM's pliability as a functional property.","method":"Fluorescent knock-in mouse (mTurq2-Col4a1), planar-sagittal live imaging, FRAP","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — FRAP and live imaging with endogenous tag; establishes COL4A1 BM stability and pliability directly","pmids":["38051393"],"is_preprint":false},{"year":1993,"finding":"At least three different nuclear proteins bind within the shared bidirectional promoter of COL4A1 and COL4A2: a CCAAT-binding protein, Sp1, and a newly identified factor 'CTCBF'; mutagenesis of binding sites showed these factors are essential for efficient transcription of both genes but with differential gene-specific effects, indicating the shared promoter functions as two overlapping gene-specific promoters with shared elements.","method":"Nuclear protein binding assays, promoter mutagenesis, transcription assays","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis of binding sites with transcriptional readout; single study","pmids":["8334157"],"is_preprint":false},{"year":1997,"finding":"The shared promoter of COL4A1 and COL4A2 has no transcriptional activity alone; efficient transcription requires cooperative effects of downstream gene-specific activating elements; mutual inhibitory interactions between the two activating elements indicate competitive interactions with the shared promoter, explaining coordinated divergent transcription.","method":"Transient transfection with reporter constructs, deletion/mutation analyses of cis-elements, factor-binding assays","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transient transfection with systematic element dissection; single lab","pmids":["9094419"],"is_preprint":false},{"year":2013,"finding":"WT1 (Wilms tumor gene) directly transactivates the Col4a1 and Col4a2 promoters cooperatively with SOX9 in Sertoli cells; loss of Wt1 causes downregulation of Col4a1/Col4a2 mRNA and protein, leading to basement membrane breakdown and testicular cord disruption, as demonstrated by luciferase and point mutation analyses of the Col4a1 promoter.","method":"Conditional Wt1 knockout, RT-PCR, Western blot, immunostaining, luciferase reporter assay, promoter point mutagenesis","journal":"Biology of reproduction","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase/mutagenesis combined with KO phenotype; single lab","pmids":["23325811"],"is_preprint":false},{"year":2015,"finding":"TGFβ1 stimulation of human vascular smooth muscle cells increases COL4A1 and COL4A2 mRNA and protein expression through SMAD3- and SMAD4-dependent canonical signaling; pharmacological inhibition of ALK5 (TGFβ receptor) or siRNA knockdown of SMAD3/SMAD4 (but not SMAD2) abolishes this induction; SMAD3 overexpression alone or TGFβ1 treatment does not alter COL4A1/COL4A2 promoter activity in luciferase assays, indicating more complex regulation beyond direct promoter binding.","method":"ALK5 inhibitor treatment, siRNA knockdown of SMAD2/3/4 in human aortic SMCs, RT-PCR, protein expression, luciferase reporter assay","journal":"Atherosclerosis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal knockdown and pharmacological approaches, primary human cells; single lab","pmids":["26310581"],"is_preprint":false},{"year":2020,"finding":"COL4A1 facilitates proliferation, migration and invasion of hepatocellular carcinoma cells through activation of FAK-Src signaling; COL4A1 expression is upregulated by transcription factor RUNX1; HCC cells with high COL4A1 expression are sensitive to FAK or Src inhibitor treatment.","method":"siRNA knockdown, western blot for FAK-Src pathway activation, RUNX1 overexpression/knockdown, FAK/Src inhibitor treatment, proliferation and migration assays","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays with pathway inhibitors and upstream regulator identification; single lab","pmids":["32746865"],"is_preprint":false},{"year":2011,"finding":"In Drosophila, col4a1 mutations have a strong antimorphic (dominant-negative) effect likely due to incorporation of mutant protein into the triple helix; col4a1 mutants display severe myopathy with centronuclear myofibers in oviduct muscle and ultrastructural A/I band disruption in larval body wall muscles; expression of a col4a1 transgene partially rescues dominant and recessive col4a1 mutant alleles but not col4a2 mutations.","method":"Complementation analysis of allelic series, transgene rescue, immunohistochemistry, electron microscopy of muscle ultrastructure","journal":"Matrix biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic genetic complementation + ultrastructural analysis in Drosophila ortholog model","pmids":["22037604"],"is_preprint":false},{"year":2019,"finding":"HTLV-1 oncoprotein Tax is sufficient to induce COL4A1 and COL4A2 transcripts in T-cells; continuous Tax expression is required for robust COL4A1/COL4A2 protein induction; Tax activates the COL4A2 and, to a lesser extent, COL4A1 promoter in luciferase assays; COL4A2 knockout in chronically infected T-cells impairs Gag transfer between T-cells but not release of virus-like particles, linking the Tax-COL4A1/A2 axis to viral biofilm formation and transmission.","method":"Transient Tax expression, siRNA/CRISPR knockout, luciferase promoter assay, co-localization imaging (COL4/Gag), virus transfer assay","journal":"Frontiers in microbiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase, KO functional assay, imaging; single lab","pmids":["31708905"],"is_preprint":false},{"year":2021,"finding":"COL4A1 binds to nidogen-1 (NID1) in oral squamous cell carcinoma cells as shown by co-immunoprecipitation; NID1 overexpression reverses the inhibitory effects of COL4A1 knockdown on cell proliferation, migration, invasion, and EMT progression, establishing COL4A1–NID1 interaction as a functional axis promoting OSCC malignancy.","method":"Co-immunoprecipitation, siRNA knockdown, NID1 overexpression rescue, proliferation/migration/invasion assays, EMT marker western blot","journal":"Experimental and therapeutic medicine","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP binding plus rescue experiment; single lab, cancer cell line model","pmids":["37006878"],"is_preprint":false},{"year":2024,"finding":"A specific COL4A1–ITGB1 interaction is highly enriched in tumorous EMT-type urothelial cells and endothelial cells; targeting COL4A1–ITGB1 with specific antibodies significantly suppresses tumorous angiogenesis and alleviates gemcitabine resistance in urothelial carcinoma.","method":"Single-cell RNA sequencing, ligand-receptor interaction analysis, antibody blockade functional assay (angiogenesis, drug resistance)","journal":"Drug resistance updates","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — receptor-ligand interaction supported by functional antibody blockade; single study","pmids":["38968684"],"is_preprint":false}],"current_model":"COL4A1 encodes the α1 chain of type IV collagen that obligatorily heterotrimer­izes with COL4A2 to form [α1(IV)]₂α2(IV), a fundamental scaffold of nearly all basement membranes; disease-causing mutations—most commonly glycine substitutions in the Gly-X-Y collagen repeat—impair folding and secretion of the heterotrimer, causing its intracellular accumulation in the ER, activation of ER/sarcoplasmic reticulum stress and the unfolded protein response, structural basement membrane deficits, and dysregulation of downstream signaling (TGFβ, integrin/FAK/ILK, NOS/NO, SR Ca²⁺/BK/TRPM4 channels); alternatively, haploinsufficiency or 3'UTR mutations that derepress miR-29-mediated suppression cause COL4A1 overexpression; collectively these mechanisms underlie a multisystem dominant disorder (Gould syndrome) affecting cerebral vasculature, eyes, kidneys, and skeletal muscle, with allelic and tissue-specific mechanistic heterogeneity determining the variable clinical expressivity."},"narrative":{"mechanistic_narrative":"COL4A1 encodes the α1 chain of type IV collagen, a core structural component of basement membranes that obligatorily assembles with COL4A2 into an [α1(IV)]₂α2(IV) heterotrimer; mutations in either chain impair secretion of the entire heterotrimer, establishing their physical and functional interdependence [PMID:22209247]. The dominant pathogenic mechanism is dominant-negative: glycine substitutions and other mutations in the Gly-X-Y collagen repeat block secretion of both mutant and normal chains, causing intracellular retention, ER stress and activation of the unfolded protein response, alongside structural deficits in vascular, ocular, renal and muscle basement membranes [PMID:15905400, PMID:16598045, PMID:16159887, PMID:17317786, PMID:20056676]. Distinct genetic mechanisms also operate: nonsense-mediated decay of truncating alleles produces haploinsufficiency [PMID:23065703], while 3'UTR mutations that disrupt a miR-29 binding site derepress COL4A1 and cause gain-of-expression cerebral small vessel disease [PMID:27666438]. Downstream of basement membrane disruption, COL4A1 mutations dysregulate multiple signaling axes — elevated TGFβ signaling drives anterior segment dysgenesis [PMID:35525525], integrin/ILK/FAK signaling (modulated by fibronectin) contributes to ocular and muscular pathology [PMID:34424299], reduced NOS activity produces vascular dysfunction [PMID:20056676], and impaired sarcoplasmic reticulum Ca²⁺ signaling blunts BK/TRPM4 channel activity and myogenic tone in cerebral vascular smooth muscle [PMID:37963192]. Pathology arises through cell-type-specific routes, with endothelial and mural cell defects driving myopathy, retinopathy and hemorrhage [PMID:28056338, PMID:26813606, PMID:29266233, PMID:37977146]. Collectively these mechanisms underlie a dominant multisystem disorder affecting cerebral vasculature, eyes, kidneys and skeletal muscle, with the folding/secretion defect being pharmacologically targetable by chemical chaperones such as 4-phenylbutyrate, though with tissue- and allele-specific outcomes [PMID:24203695, PMID:31051113, PMID:30351356, PMID:37963192].","teleology":[{"year":2005,"claim":"Established that a Col4a1 mutation acts dominantly by inhibiting secretion of both mutant and normal type IV collagen, linking the gene to vascular basement membrane integrity and cerebral hemorrhage and revealing an environmental (trauma) trigger.","evidence":"Semidominant mouse mutant characterization with cellular secretion assay, vascular BM histology, and surgical delivery intervention","pmids":["15905400","16598045"],"confidence":"High","gaps":["Did not resolve the molecular folding defect at residue level","Mechanism of trauma sensitization not defined"]},{"year":2005,"claim":"Showed that conserved glycine substitutions in the Gly-X-Y repeat exert dominant-negative effects and that allele position predicts phenotype severity, defining genotype-severity correlations across tissues.","evidence":"ENU mutagenesis allelic series in mice with histology, EM, and ophthalmological phenotyping","pmids":["16159887"],"confidence":"High","gaps":["Molecular basis of milder Yaa-residue allele not biochemically dissected","Did not address signaling consequences"]},{"year":2007,"claim":"Connected non-secretion to intracellular accumulation and ER stress, and showed genetic context (a dominant modifier) can rescue ocular phenotypes, indicating modifiable downstream pathology.","evidence":"Mouse genetics with secretion assay, ER stress markers, and genetic modifier mapping","pmids":["17317786"],"confidence":"High","gaps":["Identity of the modifier locus not defined here","Causal chain from ER stress to tissue dysgenesis incomplete"]},{"year":2007,"claim":"Mapped HANAC-associated mutations to the integrin-binding CB3[IV] region, implicating altered cell–collagen IV interactions in systemic vascular defects.","evidence":"Clinical/genetic characterization with mutation mapping to the integrin-binding domain across families","pmids":["18160688"],"confidence":"Medium","gaps":["Direct integrin-binding functional assay not reported","Causality of altered integrin engagement not experimentally tested"]},{"year":2010,"claim":"Demonstrated that mutations produce vascular dysfunction through both structural BM defects and ER stress, including reduced NOS activity and blood pressure abnormalities, broadening the mechanism beyond pure structural failure.","evidence":"Vascular function assays, NOS inhibitor pharmacology, collagen IV imaging, blood pressure and RBC measurement, UPR markers in Col4a1+/Raw mice","pmids":["20056676"],"confidence":"High","gaps":["Link between BM defect and reduced NOS activity not mechanistically resolved","RBC volume reduction mechanism unclear"]},{"year":2011,"claim":"Proved COL4A1 and COL4A2 form an obligate heterotrimer whose secretion fails when either chain is mutated, unifying the two genes' disease mechanisms.","evidence":"Reciprocal cellular secretion/ER retention assays, UPR markers, and Col4a2 mutant mouse phenotyping with ICH patient sequencing","pmids":["22209247"],"confidence":"High","gaps":["Stoichiometry/assembly kinetics not detailed","Tissue-specific differences in heterotrimer handling not addressed"]},{"year":2011,"claim":"Distinguished COL4A1 myopathy/ocular pathology from dystroglycanopathies by showing dystroglycan glycosylation is unaltered, defining a mechanistically distinct disease route.","evidence":"Mouse histology, secretion assay, and dystroglycan immunoblot/glycosylation analysis with patient mutation identification","pmids":["21625620"],"confidence":"High","gaps":["Mechanism of neuronal localization defect not defined","How BM defect translates to MEB/WWS-like features unresolved"]},{"year":2012,"claim":"Identified haploinsufficiency via nonsense-mediated decay as a pathogenic mechanism distinct from dominant-negative missense effects.","evidence":"NMD assay in patient fibroblasts, protein quantification, RT-PCR splice analysis, skin EM","pmids":["23065703"],"confidence":"High","gaps":["Why loss-of-function and dominant-negative converge on similar disease not explained","Tissue threshold for haploinsufficiency unknown"]},{"year":2012,"claim":"Extended the biosynthetic secretion defect to sporadic ICH variants, indicating a shared mechanism across familial and sporadic cerebrovascular disease.","evidence":"Cellular biosynthesis/secretion assay comparing patient vs control variants","pmids":["22522439"],"confidence":"Medium","gaps":["Only two variants tested in a single lab","No in vivo confirmation of these specific variants"]},{"year":2013,"claim":"Confirmed ER folding/secretion as a targetable mechanism by showing reduced temperature or 4-phenylbutyrate ameliorates biosynthetic defects, while documenting allele-specific biosynthetic signatures.","evidence":"Biosynthesis assays across allelic series primary cells with pharmacological/temperature rescue","pmids":["24203695"],"confidence":"High","gaps":["Allele-specific signatures not mechanistically explained","In vivo efficacy not established in this study"]},{"year":2013,"claim":"Identified WT1, cooperating with SOX9, as a direct transcriptional activator of Col4a1/Col4a2, linking gene expression control to basement membrane maintenance in Sertoli cells.","evidence":"Conditional Wt1 knockout with RT-PCR, Western blot, immunostaining, and luciferase promoter mutagenesis","pmids":["23325811"],"confidence":"Medium","gaps":["Generalizability beyond Sertoli cells untested","Direct WT1 binding site occupancy in vivo not shown"]},{"year":2015,"claim":"Defined a developmental role for the heterotrimer in glomerular basement membrane formation and linked Bowman's capsule defects to metalloproteinase induction and activated parietal epithelial cells expressing ILK and DDR1.","evidence":"G498V knock-in mouse with histology, MMP analysis, and functional renal assays","pmids":["26260163"],"confidence":"High","gaps":["Trigger linking BM defect to MMP induction unclear","Cell-intrinsic vs paracrine contributions not separated"]},{"year":2015,"claim":"Showed TGFβ1 induces COL4A1/COL4A2 expression in vascular SMCs via SMAD3/SMAD4-dependent canonical signaling, identifying an upstream cytokine regulator with regulation beyond direct promoter binding.","evidence":"ALK5 inhibitor, SMAD2/3/4 siRNA, RT-PCR, protein and luciferase assays in human aortic SMCs","pmids":["26310581"],"confidence":"Medium","gaps":["Mechanism of induction independent of direct promoter activity not resolved","Single lab, one cell type"]},{"year":2016,"claim":"Demonstrated cell-type-dependent renal mechanisms — structural BM defects driving glomerular filtration impairment versus chronic ER stress driving medullary atrophy — and a BM role in tubular aldosterone responsiveness.","evidence":"Mutant mouse phenotyping with ER stress markers, EM of BMs, and functional renal assays","pmids":["26839400"],"confidence":"High","gaps":["Why ER stress predominates in medulla without tubular BM defects unclear","Molecular basis of aldosterone resistance not defined"]},{"year":2016,"claim":"Established a primary vascular basis for progressive retinopathy by reproducing pathology with vascular-cell-specific mutation, accompanied by Müller cell activation and pro-angiogenic factor upregulation.","evidence":"Conditional vascular Col4a1 mutation with angiography, OCT, ERG, ultrastructure, and immunostaining","pmids":["26813606"],"confidence":"High","gaps":["Identity of pro-angiogenic signal not specified","Müller cell activation cause vs consequence unresolved"]},{"year":2016,"claim":"Discovered a gain-of-expression mechanism whereby disruption of a miR-29 3'UTR binding site upregulates COL4A1 and causes ischemic cerebral small vessel disease (PADMAL).","evidence":"Luciferase reporter, RT-qPCR in patient fibroblasts, and linkage/mutation screening","pmids":["27666438"],"confidence":"High","gaps":["How COL4A1 overexpression causes ischemic pathology mechanistically unknown","Tissue specificity of miR-29 derepression not addressed"]},{"year":2017,"claim":"Identified endothelial cells in muscle capillaries as the primary driver of HANAC myopathy through intracellular mutant heterotrimer accumulation, ER stress, and apoptosis.","evidence":"G498V knock-in ultrastructure, ER stress/apoptosis immunostaining, secretion analysis, and serum CK","pmids":["28056338"],"confidence":"High","gaps":["Contribution of muscle-intrinsic defects not fully separated","Apoptotic trigger downstream of ER stress not defined"]},{"year":2017,"claim":"Used conditional and temporally controlled mutation to localize ocular pathogenesis to lens cells and to an early developmental window (before E12.5).","evidence":"Cell-type-specific and temporal Col4a1 mutation with slit-lamp, OCT, IOP, and optic nerve histology","pmids":["28237965"],"confidence":"High","gaps":["Mechanism by which lens cell BM defect causes IOP dysregulation unclear","Later-stage contributions to optic nerve damage not isolated"]},{"year":2018,"claim":"Resolved two mechanistically distinct hemorrhage processes — capillary-level BBB permeability driving microhemorrhages and apoptotic smooth muscle cell loss in deep arteries driving macrohemorrhages — with retinal arterial lesions as a correlated biomarker.","evidence":"Histology, IHC, EM of brain/retinal vessels, BBB permeability assay, and parallel hemorrhage quantification in G498V mice","pmids":["29266233"],"confidence":"High","gaps":["Trigger of smooth muscle cell apoptosis not defined","Temporal relationship between micro- and macrohemorrhage unresolved"]},{"year":2019,"claim":"Demonstrated tissue-level mechanistic heterogeneity in neuromuscular disease and that secretion-promoting therapy can ameliorate or worsen myopathy depending on the mutation, establishing allele-dependent therapeutic responses.","evidence":"Mutant mouse characterization with histology, pathway analysis, and pharmacological secretion-promoting treatment","pmids":["31051113"],"confidence":"High","gaps":["Molecular basis of opposite therapeutic outcomes per allele unclear","Relative weight of muscular vs neural vs vascular insults not quantified"]},{"year":2019,"claim":"Showed 4-phenylbutyrate reduces ER stress and intracerebral hemorrhage in vivo but fails to correct eye/kidney defects or fully restore BM structure, defining tissue-specific limits of ER-stress-targeted therapy.","evidence":"Oral PBA treatment (preventive/therapeutic) with ICH quantification, ER stress markers, BM incorporation, and mechanical stress testing","pmids":["30351356"],"confidence":"High","gaps":["Why eye/kidney are PBA-refractory unexplained","Residual structural BM defect not addressed by chaperone therapy"]},{"year":2019,"claim":"Showed the HTLV-1 oncoprotein Tax induces COL4A1/COL4A2, linking the gene to viral biofilm-mediated cell-to-cell Gag transfer.","evidence":"Tax expression, CRISPR/siRNA knockout, luciferase promoter assays, colocalization imaging, and virus transfer assays in T-cells","pmids":["31708905"],"confidence":"Medium","gaps":["COL4A1-specific (vs COL4A2) contribution to transfer not isolated","Single lab"]},{"year":2020,"claim":"Identified a pro-tumorigenic role for COL4A1 in hepatocellular carcinoma via FAK-Src signaling activation, downstream of RUNX1 transcriptional control, defining a druggable axis.","evidence":"siRNA knockdown, FAK-Src Western blots, RUNX1 manipulation, FAK/Src inhibitors, and proliferation/migration assays","pmids":["32746865"],"confidence":"Medium","gaps":["Whether secreted vs intracellular COL4A1 drives signaling unclear","Single lab, cell-line based"]},{"year":2021,"claim":"Identified a single modifier locus containing Fn1 that suppresses ocular and muscular (but not cerebral) phenotypes and correlates with increased ILK and FAK phosphorylation, implicating integrin signaling in tissue-specific pathology.","evidence":"Genetic modifier screen, QTL mapping, and molecular expression analysis (Fn1, ILK, pFAK)","pmids":["34424299"],"confidence":"Medium","gaps":["Direct causal proof that Fn1 is the modifier gene incomplete","Why ICH is not suppressed unexplained"]},{"year":2021,"claim":"Identified a direct COL4A1–NID1 (nidogen-1) interaction promoting OSCC malignancy, with NID1 overexpression rescuing knockdown phenotypes.","evidence":"Co-immunoprecipitation, siRNA knockdown, NID1 rescue, and proliferation/migration/invasion/EMT assays","pmids":["37006878"],"confidence":"Medium","gaps":["Single Co-IP in one cancer cell line without reciprocal validation","Physiological relevance outside cancer untested"]},{"year":2022,"claim":"Established TGFβ signaling as a causal driver of ocular anterior segment dysgenesis downstream of COL4A1 mutation, with distinct TGFβ1/TGFβ2 roles and rescue by either secretion-promotion or TGFβ inhibition.","evidence":"Histology, TGFβ pathway analysis, genetic epistasis, and pharmacological treatment with slit-lamp phenotyping","pmids":["35525525"],"confidence":"High","gaps":["Mechanism linking BM defect to elevated TGFβ not defined","Whether TGFβ axis operates in non-ocular tissues unaddressed"]},{"year":2023,"claim":"Defined a signaling mechanism for cerebral hemorrhage: impaired sarcoplasmic reticulum Ca²⁺ signaling blunts BK/TRPM4 channel activation and myogenic vasoconstriction, disrupting cerebral autoregulation, with 4-PBA restoring function.","evidence":"Patch-clamp electrophysiology, Ca²⁺ imaging, BK/TRPM4 channel assays, myogenic tone, and PBA rescue with ICH quantification","pmids":["37963192"],"confidence":"High","gaps":["How BM/ER defect mechanistically disrupts SR Ca²⁺ handling unresolved","Generalizability across alleles untested"]},{"year":2023,"claim":"Established in a human iPSC co-culture model that mutant mural cells exhibit apoptosis, ECM remodeling and high MMP expression that paracrine-impair endothelial tight junctions, with MMP inhibition partially rescuing.","evidence":"iPSC-derived mural/endothelial co-culture, transcriptomics, ECM/MMP analysis, MMP inhibition, and tight junction assessment","pmids":["37977146"],"confidence":"High","gaps":["Identity of paracrine factor(s) not defined","Incomplete rescue indicates additional MMP-independent mechanisms"]},{"year":2023,"claim":"Demonstrated by endogenous fluorescent tagging that basement membrane collagen IV is extremely stable yet pliable, allowing basal cells to deform without detaching during epidermal growth, establishing a functional biomechanical property.","evidence":"mTurquoise2-Col4a1 knock-in mouse, planar-sagittal live imaging, and FRAP","pmids":["38051393"],"confidence":"High","gaps":["Molecular basis of BM pliability not dissected","How disease mutations alter this property untested"]},{"year":2024,"claim":"Identified a COL4A1–ITGB1 ligand-receptor interaction enriched in tumor EMT-type and endothelial cells whose antibody blockade suppresses angiogenesis and reverses gemcitabine resistance.","evidence":"Single-cell RNA-seq, ligand-receptor analysis, and antibody blockade functional assays in urothelial carcinoma","pmids":["38968684"],"confidence":"Medium","gaps":["Direct biochemical COL4A1-ITGB1 binding not validated","Single study"]},{"year":null,"claim":"How the upstream structural/ER-stress defect mechanistically connects to the diverse downstream signaling derangements (TGFβ elevation, integrin/ILK/FAK activation, SR Ca²⁺ and BK/TRPM4 disruption, NOS reduction) — and why these couplings and therapeutic responses are tissue- and allele-specific — remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No unifying molecular link from BM/ER defect to each signaling axis","Allele-specific therapeutic divergence mechanistically unexplained","Tissue-specificity of refractoriness to chaperone therapy not understood"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,1,4,23]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[9,32]}],"localization":[{"term_id":"GO:0030312","term_label":"external encapsulating structure","supporting_discovery_ids":[0,1,4,10,23]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[2,3,4,13]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[8,23]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[0,4,10,23]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[2,3,4,13]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,6,12,18]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[20,21,28]}],"complexes":["[α1(IV)]₂α2(IV) type IV collagen heterotrimer"],"partners":["COL4A2","NID1","ITGB1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P02462","full_name":"Collagen alpha-1(IV) chain","aliases":[],"length_aa":1669,"mass_kda":160.6,"function":"Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen Arresten, comprising the C-terminal NC1 domain, inhibits angiogenesis and tumor formation. The C-terminal half is found to possess the anti-angiogenic activity. Specifically inhibits endothelial cell proliferation, migration and tube formation","subcellular_location":"Secreted, extracellular space, extracellular matrix, basement membrane","url":"https://www.uniprot.org/uniprotkb/P02462/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/COL4A1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/COL4A1","total_profiled":1310},"omim":[{"mim_id":"618564","title":"MICROANGIOPATHY AND LEUKOENCEPHALOPATHY, PONTINE, AUTOSOMAL DOMINANT; PADMAL","url":"https://www.omim.org/entry/618564"},{"mim_id":"618360","title":"BRAIN SMALL VESSEL DISEASE 3; BSVD3","url":"https://www.omim.org/entry/618360"},{"mim_id":"617531","title":"COLLAGEN BETA(1-O)GALACTOSYLTRANSFERASE 1; COLGALT1","url":"https://www.omim.org/entry/617531"},{"mim_id":"614519","title":"HEMORRHAGE, INTRACEREBRAL, SUSCEPTIBILITY TO; ICH","url":"https://www.omim.org/entry/614519"},{"mim_id":"614483","title":"BRAIN SMALL VESSEL DISEASE 2A, AUTOSOMAL DOMINANT; BSVD2A","url":"https://www.omim.org/entry/614483"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"placenta","ntpm":846.2}],"url":"https://www.proteinatlas.org/search/COL4A1"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P02462","domains":[{"cath_id":"2.170.240.10","chopping":"1447-1506_1513-1640_1655-1668","consensus_level":"medium","plddt":96.0146,"start":1447,"end":1668}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P02462","model_url":"https://alphafold.ebi.ac.uk/files/AF-P02462-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P02462-F1-predicted_aligned_error_v6.png","plddt_mean":48.47},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=COL4A1","jax_strain_url":"https://www.jax.org/strain/search?query=COL4A1"},"sequence":{"accession":"P02462","fasta_url":"https://rest.uniprot.org/uniprotkb/P02462.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P02462/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P02462"}},"corpus_meta":[{"pmid":"16598045","id":"PMC_16598045","title":"Role of COL4A1 in small-vessel disease and hemorrhagic stroke.","date":"2006","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16598045","citation_count":432,"is_preprint":false},{"pmid":"15905400","id":"PMC_15905400","title":"Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly.","date":"2005","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15905400","citation_count":426,"is_preprint":false},{"pmid":"18160688","id":"PMC_18160688","title":"COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps.","date":"2007","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18160688","citation_count":271,"is_preprint":false},{"pmid":"25719457","id":"PMC_25719457","title":"The expanding phenotype of COL4A1 and COL4A2 mutations: clinical data on 13 newly identified families and a review of the literature.","date":"2015","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25719457","citation_count":247,"is_preprint":false},{"pmid":"20558831","id":"PMC_20558831","title":"COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review.","date":"2010","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/20558831","citation_count":177,"is_preprint":false},{"pmid":"22209247","id":"PMC_22209247","title":"COL4A2 mutations impair COL4A1 and COL4A2 secretion and cause hemorrhagic stroke.","date":"2011","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22209247","citation_count":169,"is_preprint":false},{"pmid":"23225343","id":"PMC_23225343","title":"Phenotypic spectrum of COL4A1 mutations: porencephaly to schizencephaly.","date":"2012","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23225343","citation_count":127,"is_preprint":false},{"pmid":"16107487","id":"PMC_16107487","title":"Novel mutations in three families confirm a major role of COL4A1 in hereditary porencephaly.","date":"2005","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16107487","citation_count":125,"is_preprint":false},{"pmid":"17696175","id":"PMC_17696175","title":"COL4A1 mutation in Axenfeld-Rieger anomaly with leukoencephalopathy and stroke.","date":"2007","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/17696175","citation_count":123,"is_preprint":false},{"pmid":"16159887","id":"PMC_16159887","title":"Dominant mutations of Col4a1 result in basement membrane defects which lead to anterior segment dysgenesis and glomerulopathy.","date":"2005","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16159887","citation_count":123,"is_preprint":false},{"pmid":"21625620","id":"PMC_21625620","title":"COL4A1 mutations cause ocular dysgenesis, neuronal localization defects, and myopathy in mice and Walker-Warburg syndrome in humans.","date":"2011","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21625620","citation_count":117,"is_preprint":false},{"pmid":"32746865","id":"PMC_32746865","title":"COL4A1 promotes the growth and metastasis of hepatocellular carcinoma cells by activating FAK-Src signaling.","date":"2020","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/32746865","citation_count":116,"is_preprint":false},{"pmid":"17317786","id":"PMC_17317786","title":"Col4a1 mutation causes endoplasmic reticulum stress and genetically modifiable ocular dysgenesis.","date":"2007","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17317786","citation_count":115,"is_preprint":false},{"pmid":"21157337","id":"PMC_21157337","title":"Clinical spectrum of type IV collagen (COL4A1) mutations: a novel genetic multisystem disease.","date":"2011","source":"Current opinion in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21157337","citation_count":109,"is_preprint":false},{"pmid":"17179069","id":"PMC_17179069","title":"Type IV procollagen missense mutations associated with defects of the eye, vascular stability, the brain, kidney function and embryonic or postnatal viability in the mouse, Mus musculus: an extension of the Col4a1 allelic series and the identification of the first two Col4a2 mutant alleles.","date":"2006","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17179069","citation_count":109,"is_preprint":false},{"pmid":"25653287","id":"PMC_25653287","title":"Common variation in COL4A1/COL4A2 is associated with sporadic cerebral small vessel disease.","date":"2015","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25653287","citation_count":106,"is_preprint":false},{"pmid":"19949034","id":"PMC_19949034","title":"Cerebrovascular disease related to COL4A1 mutations in HANAC syndrome.","date":"2009","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19949034","citation_count":102,"is_preprint":false},{"pmid":"22522439","id":"PMC_22522439","title":"COL4A1 mutations in patients with sporadic late-onset intracerebral hemorrhage.","date":"2012","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/22522439","citation_count":97,"is_preprint":false},{"pmid":"17379824","id":"PMC_17379824","title":"COL4A1 mutation in a patient with sporadic, recurrent intracerebral hemorrhage.","date":"2007","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/17379824","citation_count":96,"is_preprint":false},{"pmid":"19194877","id":"PMC_19194877","title":"COL4A1 mutation in two preterm siblings with antenatal onset of parenchymal hemorrhage.","date":"2009","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19194877","citation_count":94,"is_preprint":false},{"pmid":"28415608","id":"PMC_28415608","title":"Collagen type IV alpha 1 (COL4A1) and collagen type XIII alpha 1 (COL13A1) produced in cancer cells promote tumor budding at the invasion front in human urothelial carcinoma of the bladder.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28415608","citation_count":92,"is_preprint":false},{"pmid":"20818663","id":"PMC_20818663","title":"Novel COL4A1 mutations associated with HANAC syndrome: a role for the triple helical CB3[IV] domain.","date":"2010","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/20818663","citation_count":78,"is_preprint":false},{"pmid":"27666438","id":"PMC_27666438","title":"Disruption of a miR-29 binding site leading to COL4A1 upregulation causes pontine autosomal dominant microangiopathy with leukoencephalopathy.","date":"2016","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27666438","citation_count":78,"is_preprint":false},{"pmid":"24203695","id":"PMC_24203695","title":"Allelic heterogeneity contributes to variability in ocular dysgenesis, myopathy and brain malformations caused by Col4a1 and Col4a2 mutations.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24203695","citation_count":72,"is_preprint":false},{"pmid":"22574627","id":"PMC_22574627","title":"Childhood presentation of COL4A1 mutations.","date":"2012","source":"Developmental medicine and child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/22574627","citation_count":69,"is_preprint":false},{"pmid":"17938367","id":"PMC_17938367","title":"Clinical and brain MRI follow-up study of a family with COL4A1 mutation.","date":"2007","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/17938367","citation_count":66,"is_preprint":false},{"pmid":"20056676","id":"PMC_20056676","title":"Col4a1 mutation in mice causes defects in vascular function and low blood pressure associated with reduced red blood cell volume.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20056676","citation_count":65,"is_preprint":false},{"pmid":"19840616","id":"PMC_19840616","title":"COL4A1 mutation in preterm intraventricular hemorrhage.","date":"2009","source":"The Journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/19840616","citation_count":59,"is_preprint":false},{"pmid":"27389912","id":"PMC_27389912","title":"Coronary-Heart-Disease-Associated Genetic Variant at the COL4A1/COL4A2 Locus Affects COL4A1/COL4A2 Expression, Vascular Cell Survival, Atherosclerotic Plaque Stability and Risk of Myocardial Infarction.","date":"2016","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27389912","citation_count":58,"is_preprint":false},{"pmid":"19477666","id":"PMC_19477666","title":"A dominantly inherited mutation in collagen IV A1 (COL4A1) causing childhood onset stroke without porencephaly.","date":"2009","source":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society","url":"https://pubmed.ncbi.nlm.nih.gov/19477666","citation_count":58,"is_preprint":false},{"pmid":"20385946","id":"PMC_20385946","title":"Ophthalmological features associated with COL4A1 mutations.","date":"2010","source":"Archives of ophthalmology (Chicago, Ill. : 1960)","url":"https://pubmed.ncbi.nlm.nih.gov/20385946","citation_count":57,"is_preprint":false},{"pmid":"21500141","id":"PMC_21500141","title":"Fetal origin of brain damage in 2 infants with a COL4A1 mutation: fetal and neonatal MRI.","date":"2011","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/21500141","citation_count":50,"is_preprint":false},{"pmid":"24628545","id":"PMC_24628545","title":"Whole exome analysis identifies dominant COL4A1 mutations in patients with complex ocular phenotypes involving microphthalmia.","date":"2014","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24628545","citation_count":49,"is_preprint":false},{"pmid":"26260163","id":"PMC_26260163","title":"HANAC Syndrome Col4a1 Mutation Causes Neonate Glomerular Hyperpermeability and Adult Glomerulocystic Kidney Disease.","date":"2015","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/26260163","citation_count":48,"is_preprint":false},{"pmid":"31051113","id":"PMC_31051113","title":"COL4A1 Mutations Cause Neuromuscular Disease with Tissue-Specific Mechanistic Heterogeneity.","date":"2019","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31051113","citation_count":48,"is_preprint":false},{"pmid":"23065703","id":"PMC_23065703","title":"Novel COL4A1 mutations cause cerebral small vessel disease by haploinsufficiency.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23065703","citation_count":47,"is_preprint":false},{"pmid":"36324412","id":"PMC_36324412","title":"Main features of COL4A1-COL4A2 related cerebral microangiopathies.","date":"2022","source":"Cerebral circulation - cognition and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/36324412","citation_count":46,"is_preprint":false},{"pmid":"28938546","id":"PMC_28938546","title":"The highly expressed COL4A1 genes contributes to the proliferation and migration of the invasive ductal carcinomas.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28938546","citation_count":45,"is_preprint":false},{"pmid":"26813606","id":"PMC_26813606","title":"Col4a1 mutations cause progressive retinal neovascular defects and retinopathy.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26813606","citation_count":44,"is_preprint":false},{"pmid":"20166936","id":"PMC_20166936","title":"Role of COL4A1 in basement-membrane integrity and cerebral small-vessel disease. The COL4A1 stroke syndrome.","date":"2010","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20166936","citation_count":43,"is_preprint":false},{"pmid":"31905170","id":"PMC_31905170","title":"The correlation and role analysis of COL4A1 and COL4A2 in hepatocarcinogenesis.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31905170","citation_count":42,"is_preprint":false},{"pmid":"26839400","id":"PMC_26839400","title":"ER stress and basement membrane defects combine to cause glomerular and tubular renal disease resulting from Col4a1 mutations in mice.","date":"2016","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/26839400","citation_count":42,"is_preprint":false},{"pmid":"22134833","id":"PMC_22134833","title":"COL4A1 mutations associated with a characteristic pattern of intracranial calcification.","date":"2011","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/22134833","citation_count":42,"is_preprint":false},{"pmid":"26310581","id":"PMC_26310581","title":"Functional interaction between COL4A1/COL4A2 and SMAD3 risk loci for coronary artery disease.","date":"2015","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/26310581","citation_count":41,"is_preprint":false},{"pmid":"29266233","id":"PMC_29266233","title":"Severity of arterial defects in the retina correlates with the burden of intracerebral haemorrhage in COL4A1-related stroke.","date":"2018","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29266233","citation_count":37,"is_preprint":false},{"pmid":"8334157","id":"PMC_8334157","title":"Differential effects of DNA-binding proteins on bidirectional transcription from the common promoter region of human collagen type IV genes COL4A1 and COL4A2.","date":"1993","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/8334157","citation_count":37,"is_preprint":false},{"pmid":"22037604","id":"PMC_22037604","title":"Drosophila basement membrane collagen col4a1 mutations cause severe myopathy.","date":"2011","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/22037604","citation_count":36,"is_preprint":false},{"pmid":"38968684","id":"PMC_38968684","title":"A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis.","date":"2024","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/38968684","citation_count":35,"is_preprint":false},{"pmid":"33890394","id":"PMC_33890394","title":"miR-543 in human mesenchymal stem cell-derived exosomes promotes cardiac microvascular endothelial cell angiogenesis after myocardial infarction through COL4A1.","date":"2021","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/33890394","citation_count":35,"is_preprint":false},{"pmid":"32515830","id":"PMC_32515830","title":"Prevalence of COL4A1 and COL4A2 mutations in severe fetal multifocal hemorrhagic and/or ischemic cerebral lesions.","date":"2021","source":"Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/32515830","citation_count":34,"is_preprint":false},{"pmid":"25228067","id":"PMC_25228067","title":"Next generation sequencing uncovers a missense mutation in COL4A1 as the cause of familial retinal arteriolar tortuosity.","date":"2014","source":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","url":"https://pubmed.ncbi.nlm.nih.gov/25228067","citation_count":34,"is_preprint":false},{"pmid":"29395486","id":"PMC_29395486","title":"The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations.","date":"2018","source":"American journal of kidney diseases : the official journal of the National Kidney Foundation","url":"https://pubmed.ncbi.nlm.nih.gov/29395486","citation_count":33,"is_preprint":false},{"pmid":"30315939","id":"PMC_30315939","title":"Further refinement of COL4A1 and COL4A2 related cortical malformations.","date":"2018","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30315939","citation_count":32,"is_preprint":false},{"pmid":"23325811","id":"PMC_23325811","title":"The Wilms tumor gene, Wt1, maintains testicular cord integrity by regulating the expression of Col4a1 and Col4a2.","date":"2013","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/23325811","citation_count":32,"is_preprint":false},{"pmid":"30351356","id":"PMC_30351356","title":"4-Sodium phenyl butyric acid has both efficacy and counter-indicative effects in the treatment of Col4a1 disease.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30351356","citation_count":32,"is_preprint":false},{"pmid":"32732225","id":"PMC_32732225","title":"Prenatal clinical manifestations in individuals with COL4A1/2 variants.","date":"2020","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32732225","citation_count":31,"is_preprint":false},{"pmid":"9094419","id":"PMC_9094419","title":"Cooperative and competitive interactions of regulatory elements are involved in the control of divergent transcription of human Col4A1 and Col4A2 genes.","date":"1997","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9094419","citation_count":31,"is_preprint":false},{"pmid":"28056338","id":"PMC_28056338","title":"HANAC Col4a1 Mutation in Mice Leads to Skeletal Muscle Alterations due to a Primary Vascular Defect.","date":"2017","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28056338","citation_count":29,"is_preprint":false},{"pmid":"33891266","id":"PMC_33891266","title":"COL4A1, negatively regulated by XPD and miR-29a-3p, promotes cell proliferation, migration, invasion and epithelial-mesenchymal transition in liver cancer cells.","date":"2021","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/33891266","citation_count":28,"is_preprint":false},{"pmid":"35297303","id":"PMC_35297303","title":"Collagen type IV alpha 1 (COL4A1) silence hampers the invasion, migration and epithelial-mesenchymal transition (EMT) of gastric cancer cells through blocking Hedgehog signaling pathway.","date":"2022","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/35297303","citation_count":26,"is_preprint":false},{"pmid":"31201347","id":"PMC_31201347","title":"miR-29c overexpression and COL4A1 downregulation in infertile human endometrium reduces endometrial epithelial cell adhesive capacity in vitro implying roles in receptivity.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31201347","citation_count":26,"is_preprint":false},{"pmid":"35184134","id":"PMC_35184134","title":"LncRNA SND1-IT1 facilitates TGF-β1-induced epithelial-to-mesenchymal transition via miR-124/COL4A1 axis in gastric cancer.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35184134","citation_count":26,"is_preprint":false},{"pmid":"26567795","id":"PMC_26567795","title":"Strain-Dependent Anterior Segment Dysgenesis and Progression to Glaucoma in Col4a1 Mutant Mice.","date":"2015","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/26567795","citation_count":26,"is_preprint":false},{"pmid":"24374867","id":"PMC_24374867","title":"Fetal intracerebral hemorrhage and cataract: think COL4A1.","date":"2014","source":"Journal of perinatology : official journal of the California Perinatal Association","url":"https://pubmed.ncbi.nlm.nih.gov/24374867","citation_count":26,"is_preprint":false},{"pmid":"21527998","id":"PMC_21527998","title":"Sequence variants in COL4A1 and COL4A2 genes in Ecuadorian families with keratoconus.","date":"2011","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/21527998","citation_count":25,"is_preprint":false},{"pmid":"3224982","id":"PMC_3224982","title":"Macrorestriction mapping of COL4A1 and COL4A2 collagen genes on human chromosome 13q34.","date":"1988","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/3224982","citation_count":24,"is_preprint":false},{"pmid":"23394911","id":"PMC_23394911","title":"Variants of anterior segment dysgenesis and cerebral involvement in a large family with a novel COL4A1 mutation.","date":"2013","source":"American journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/23394911","citation_count":24,"is_preprint":false},{"pmid":"28237965","id":"PMC_28237965","title":"Genetic dissection of anterior segment dysgenesis caused by a Col4a1 mutation in mouse.","date":"2017","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/28237965","citation_count":23,"is_preprint":false},{"pmid":"27190376","id":"PMC_27190376","title":"A novel COL4A1 frameshift mutation in familial kidney disease: the importance of the C-terminal NC1 domain of type IV collagen.","date":"2016","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/27190376","citation_count":23,"is_preprint":false},{"pmid":"31708905","id":"PMC_31708905","title":"Collagen IV (COL4A1, COL4A2), a Component of the Viral Biofilm, Is Induced by the HTLV-1 Oncoprotein Tax and Impacts Virus Transmission.","date":"2019","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/31708905","citation_count":23,"is_preprint":false},{"pmid":"25124159","id":"PMC_25124159","title":"A novel COL4A1 gene mutation results in autosomal dominant non-syndromic congenital cataract in a Chinese family.","date":"2014","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25124159","citation_count":22,"is_preprint":false},{"pmid":"25425218","id":"PMC_25425218","title":"Porencephaly in a fetus and HANAC in her father: variable expression of COL4A1 mutation.","date":"2014","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/25425218","citation_count":21,"is_preprint":false},{"pmid":"34424299","id":"PMC_34424299","title":"Identification of fibronectin 1 as a candidate genetic modifier in a Col4a1 mutant mouse model of Gould syndrome.","date":"2021","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/34424299","citation_count":21,"is_preprint":false},{"pmid":"32467996","id":"PMC_32467996","title":"miR‑29 mediates exercise‑induced skeletal muscle angiogenesis by targeting VEGFA, COL4A1 and COL4A2 via the PI3K/Akt signaling pathway.","date":"2020","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/32467996","citation_count":20,"is_preprint":false},{"pmid":"22573493","id":"PMC_22573493","title":"MiR-21 is enriched in the RNA-induced silencing complex and targets COL4A1 in human granulosa cell lines.","date":"2012","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/22573493","citation_count":20,"is_preprint":false},{"pmid":"28043398","id":"PMC_28043398","title":"COL4A1 Mutation in a Neonate With Intrauterine Stroke and Anterior Segment Dysgenesis.","date":"2016","source":"Pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28043398","citation_count":19,"is_preprint":false},{"pmid":"37963192","id":"PMC_37963192","title":"Impaired intracellular Ca2+ signaling contributes to age-related cerebral small vessel disease in Col4a1 mutant mice.","date":"2023","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/37963192","citation_count":19,"is_preprint":false},{"pmid":"37977146","id":"PMC_37977146","title":"A novel human iPSC model of COL4A1/A2 small vessel disease unveils a key pathogenic role of matrix metalloproteinases.","date":"2023","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37977146","citation_count":19,"is_preprint":false},{"pmid":"22932948","id":"PMC_22932948","title":"COL4A1-related disease: raised creatine kinase and cerebral calcification as useful pointers.","date":"2012","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/22932948","citation_count":19,"is_preprint":false},{"pmid":"35150448","id":"PMC_35150448","title":"COL4A1/COL4A2 and inherited platelet disorder gene variants in fetuses showing intracranial hemorrhage.","date":"2022","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/35150448","citation_count":18,"is_preprint":false},{"pmid":"33234027","id":"PMC_33234027","title":"Overexpression of DDR1 Promotes Migration, Invasion, Though EMT-Related Molecule Expression and COL4A1/DDR1/MMP-2 Signaling Axis.","date":"2020","source":"Technology in cancer research & treatment","url":"https://pubmed.ncbi.nlm.nih.gov/33234027","citation_count":18,"is_preprint":false},{"pmid":"32165822","id":"PMC_32165822","title":"Role of the XIST-miR-181a-COL4A1 axis in the development and progression of keratoconus.","date":"2020","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/32165822","citation_count":17,"is_preprint":false},{"pmid":"33830670","id":"PMC_33830670","title":"Novel COL4A1-VEGFD gene fusion in myofibroma.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33830670","citation_count":16,"is_preprint":false},{"pmid":"25873210","id":"PMC_25873210","title":"Two families with novel missense mutations in COL4A1: When diagnosis can be missed.","date":"2015","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25873210","citation_count":16,"is_preprint":false},{"pmid":"3674752","id":"PMC_3674752","title":"The human alpha 2(IV) collagen gene, COL4A2, is syntenic with the alpha 1(IV) gene, COL4A1, on chromosome 13.","date":"1987","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/3674752","citation_count":16,"is_preprint":false},{"pmid":"35525525","id":"PMC_35525525","title":"Elevated TGFβ signaling contributes to ocular anterior segment dysgenesis in Col4a1 mutant mice.","date":"2022","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/35525525","citation_count":15,"is_preprint":false},{"pmid":"31366314","id":"PMC_31366314","title":"Cervical Spinal Involvement in a Chinese Pedigree With Pontine Autosomal Dominant Microangiopathy and Leukoencephalopathy Caused by a 3' Untranslated Region Mutation of COL4A1 Gene.","date":"2019","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/31366314","citation_count":15,"is_preprint":false},{"pmid":"38481388","id":"PMC_38481388","title":"Integrating single-cell and spatial transcriptomes reveals COL4A1/2 facilitates the spatial organisation of stromal cells differentiation in breast phyllodes tumours.","date":"2024","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38481388","citation_count":14,"is_preprint":false},{"pmid":"38051393","id":"PMC_38051393","title":"An mTurq2-Col4a1 mouse model allows for live visualization of mammalian basement membrane development.","date":"2023","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/38051393","citation_count":14,"is_preprint":false},{"pmid":"32565804","id":"PMC_32565804","title":"Effect of COL4A1 Expression on the Survival of Neoadjuvant Chemotherapy Breast Cancer Patients.","date":"2020","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32565804","citation_count":14,"is_preprint":false},{"pmid":"29760938","id":"PMC_29760938","title":"Novel COL4A1 mutation in a fetus with early prenatal onset of schizencephaly.","date":"2018","source":"Human genome variation","url":"https://pubmed.ncbi.nlm.nih.gov/29760938","citation_count":14,"is_preprint":false},{"pmid":"37006878","id":"PMC_37006878","title":"COL4A1 promotes the proliferation and migration of oral squamous cell carcinoma cells by binding to NID1.","date":"2023","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37006878","citation_count":13,"is_preprint":false},{"pmid":"34415564","id":"PMC_34415564","title":"A Novel Mutation in COL4A1 Gene in a Chinese Family with Pontine Autosomal Dominant Microangiopathy and Leukoencephalopathy.","date":"2021","source":"Translational stroke research","url":"https://pubmed.ncbi.nlm.nih.gov/34415564","citation_count":13,"is_preprint":false},{"pmid":"26748532","id":"PMC_26748532","title":"Association of COL4A1 gene polymorphisms with cerebral palsy in a Chinese Han population.","date":"2016","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26748532","citation_count":12,"is_preprint":false},{"pmid":"26120313","id":"PMC_26120313","title":"Case of Small Vessel Disease Associated with COL4A1 Mutations following Trauma.","date":"2015","source":"Case reports in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26120313","citation_count":12,"is_preprint":false},{"pmid":"31808207","id":"PMC_31808207","title":"Cerebral small vessel disease with hemorrhagic stroke related to COL4A1 mutation: A case report.","date":"2019","source":"Neuropathology : official journal of the Japanese Society of Neuropathology","url":"https://pubmed.ncbi.nlm.nih.gov/31808207","citation_count":12,"is_preprint":false},{"pmid":"28017902","id":"PMC_28017902","title":"A severe pulmonary complication in a patient with COL4A1-related disorder: A case report.","date":"2016","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28017902","citation_count":12,"is_preprint":false},{"pmid":"40616396","id":"PMC_40616396","title":"COL4A1 and COL4A2-related disorders: Clinical features, diagnostic guidelines, and management.","date":"2025","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40616396","citation_count":11,"is_preprint":false},{"pmid":"35122350","id":"PMC_35122350","title":"FOXL2 regulates the expression of the Col4a1 collagen gene in chicken granulosa cells.","date":"2022","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/35122350","citation_count":11,"is_preprint":false},{"pmid":"34565019","id":"PMC_34565019","title":"METTL3 participates in glioma development by regulating the methylation level of COL4A1.","date":"2021","source":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34565019","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50249,"output_tokens":8516,"usd":0.139243,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18688,"output_tokens":8240,"usd":0.14972,"stage2_stop_reason":"end_turn"},"total_usd":0.288963,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"A semidominant missense mutation in Col4a1 (in-frame deletion of exon 40) inhibits secretion of both mutant and normal type IV collagen, causing focal disruptions of vascular basement membranes and perinatal cerebral hemorrhage/porencephaly in mice; surgical delivery alleviated birth-associated hemorrhage, demonstrating that environmental trauma conspires with the mutation.\",\n      \"method\": \"Mouse genetics (semidominant mutant characterization), cellular secretion assay, histology of vascular basement membranes, surgical intervention experiment\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (genetic, cellular biosynthesis assay, surgical rescue), replicated across two papers (PMID:15905400, PMID:16598045)\",\n      \"pmids\": [\"15905400\", \"16598045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Dominant missense mutations affecting conserved glycine residues in the Gly-X-Y collagen repeat of Col4a1 cause dominant-negative effects on expression and function of the major collagen IV isoform α1(IV), leading to basement membrane defects in the eye (Axenfeld-Rieger-like anterior segment dysgenesis, glaucoma) and kidney (glomerulopathy); a milder allele with a Yaa-residue mutation produces a less severe phenotype, establishing allele-severity correlations.\",\n      \"method\": \"ENU mutagenesis allelic series in mice, histology, electron microscopy of basement membranes, slit-lamp and ophthalmological phenotyping\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — allelic series with multiple orthogonal methods; replicated in subsequent studies\",\n      \"pmids\": [\"16159887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A Col4a1 missense mutation causes non-secretion of mutant COL4A1 proteins, which accumulate intracellularly, induces endoplasmic reticulum (ER) stress, and leads to anterior segment dysgenesis and optic nerve hypoplasia; the overall phenotypic consequence depends on genetic context, with a single dominant modifier locus capable of rescuing both ASD and optic nerve hypoplasia.\",\n      \"method\": \"Mouse genetics, protein secretion assay, ER stress markers, genetic modifier mapping\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (biosynthesis assay, ER stress markers, genetic modifier screen) in one study\",\n      \"pmids\": [\"17317786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Col4a1 missense mutation (Col4a1+/Raw) in mice causes focal endothelial detachment from the media, impaired collagen IV deposition in vascular basement membranes, activation of the unfolded protein response, reduced basal nitric oxide synthase (NOS) activity, age-dependent hypersensitivity to acetylcholine abolished by NOS inhibition, and reduced red blood cell volume causing hypotension; together these establish that COL4A1 mutations produce complex vascular dysfunction through both structural basement membrane defects and ER stress.\",\n      \"method\": \"Vascular function assays (vasoconstriction/vasodilation), NOS inhibitor pharmacology, collagen IV immunostaining/electron microscopy, blood pressure measurement, red blood cell counting, unfolded protein response markers\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal functional and molecular methods in a single study with clear mechanistic readouts\",\n      \"pmids\": [\"20056676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"COL4A2 mutations (identified in ICH patients) cause intracellular retention of both COL4A1 and COL4A2 within the endoplasmic reticulum at the expense of their secretion, trigger ER stress and activate the unfolded protein response; Col4a2 mutant mice have completely penetrant intracerebral hemorrhage, establishing that COL4A1 and COL4A2 form heterotrimers and that mutations in either chain impair secretion of the entire heterotrimer.\",\n      \"method\": \"Cellular secretion assay, ER retention immunostaining, unfolded protein response markers, Col4a2 mutant mouse phenotyping, sequencing of ICH patients\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal cellular assays, mouse model, UPR markers; multiple orthogonal methods\",\n      \"pmids\": [\"22209247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Heterozygous Col4a1 mutations in mice cause ocular dysgenesis, neuronal localization defects, and myopathy characteristic of MEB/WWS; at least one mutation interferes with secretion of mutant proteins causing intracellular accumulation; dystroglycan expression and post-translational modification are unaltered in Col4a1 mutant mice, establishing that COL4A1 mutations represent a pathogenic mechanism distinct from dystroglycan glycosylation defects.\",\n      \"method\": \"Histology, molecular and biochemical approaches (secretion assay, dystroglycan immunoblot/glycosylation analysis), patient mutation identification\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (biosynthesis assay, histology, negative dystroglycan result as mechanistic discriminator)\",\n      \"pmids\": [\"21625620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Two novel COL4A1 mutations (a frameshift c.2085del and a splice-site mutation c.2194-1G>A) cause nonsense-mediated decay (NMD) of mutant COL4A1 mRNA and a clear reduction in COL4A1 protein, establishing haploinsufficiency as a distinct pathogenic mechanism (in addition to the dominant-negative mechanism seen with missense mutations) for COL4A1-related cerebral small vessel disease; capillary basement membrane thickening was also documented in patient skin.\",\n      \"method\": \"NMD assay in patient fibroblasts, COL4A1 protein quantification, RT-PCR splice analysis, skin electron microscopy\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — NMD demonstrated in patient-derived cells with multiple molecular readouts in one study\",\n      \"pmids\": [\"23065703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Putative COL4A1 mutations found in sporadic ICH patients (P352L and R538G), but not variants from ICH-free controls, impair COL4A1 secretion in a cellular assay, demonstrating a shared biosynthetic mechanism across an allelic series causing both familial and sporadic cerebrovascular disease.\",\n      \"method\": \"COL4A1 biosynthesis/secretion assay in cell culture, sequencing of sporadic ICH patients vs. controls\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — cellular secretion assay, single lab, two variants tested\",\n      \"pmids\": [\"22522439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"COL4A1 and COL4A2 mutations cause increased intracellular and decreased extracellular protein for most alleles, but allelic heterogeneity produces distinct biosynthetic signatures for some mutations; reduced temperature or 4-phenylbutyrate treatment ameliorated biosynthetic defects in primary cell lines from mutant mice, confirming ER folding/secretion as a targetable mechanism.\",\n      \"method\": \"Biosynthesis assay (intracellular/extracellular protein quantification) in primary cells from allelic series mutant mice, pharmacological rescue with 4-PBA and reduced temperature\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple alleles, multiple methods, pharmacological rescue; one rigorous study\",\n      \"pmids\": [\"24203695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"All six COL4A1 mutations associated with HANAC syndrome localize within the CB3[IV] fragment of the collagenous domain, which encompasses major integrin-binding sites, suggesting that abnormal cell–type IV collagen interactions (via integrin binding sites) underlie the systemic vascular defects in HANAC.\",\n      \"method\": \"Clinical and genetic characterization, mutation mapping to functional domain (CB3[IV] integrin-binding region), sequencing of affected families\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — domain mapping across multiple families establishes genotype-structure correlation, but direct integrin-binding functional assay not reported in abstract\",\n      \"pmids\": [\"18160688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The HANAC Col4a1 p.Gly498Val mutation in knock-in mice causes delayed glomerulogenesis and podocyte differentiation, leading to neonatal albuminuria; in adult mice, Bowman's capsule abnormalities are associated with metalloproteinase induction, activation of parietal epithelial cells (expressing CD44, α-SMA, ILK, DDR1), inflammatory infiltrates, and glomerular cyst development; homozygous mice additionally show dysmorphic papillae and urinary concentration defects, revealing a developmental role for the α1α1α2(IV) heterotrimer in the embryonic glomerular basement membrane.\",\n      \"method\": \"Knock-in mouse model, histology/immunostaining, metalloproteinase expression analysis, functional renal assays (albuminuria, hematuria, urinary concentration)\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knock-in mouse with multiple orthogonal molecular and functional readouts in one study\",\n      \"pmids\": [\"26260163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ER stress and basement membrane defects both contribute to Col4a1 renal disease in mice: glomerular/Bowman's capsule structural BM defects cause glomerular filtration impairment, while medullary atrophy is associated with chronic ER stress without tubular basement membrane defects, demonstrating cell-type-dependent molecular mechanisms; impaired tubular sodium reabsorption despite elevated aldosterone indicates BM modulation of tubular aldosterone response.\",\n      \"method\": \"Col4a1 mutant mouse phenotyping, ER stress marker analysis, electron microscopy of BMs, functional renal assays (proteinuria, aquaporin 2 expression, aldosterone levels)\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (EM, biochemical, physiological) demonstrating tissue-specific mechanistic heterogeneity\",\n      \"pmids\": [\"26839400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Disruption of a miR-29 binding site in the 3'UTR of COL4A1 causes upregulation of COL4A1 expression, establishing that gain-of-function COL4A1 overexpression (not just loss-of-function missense mutations) causes a severe ischemic cerebral small vessel disease (PADMAL); demonstrated by luciferase reporter assays and RT-qPCR in patient fibroblasts.\",\n      \"method\": \"Luciferase reporter assay, RT-qPCR of patient fibroblasts, linkage analysis, mutation screening of cSVD cohort\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase and RT-qPCR in patient-derived cells with cosegregation; establishes novel gain-of-expression mechanism\",\n      \"pmids\": [\"27666438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In a HANAC Col4a1 G498V knock-in mouse model, skeletal muscle myopathy is primarily driven by endothelial cell defects in muscle capillaries: endothelial cells accumulate mutant α1α1α2(IV) intracellularly, show ER cisternae dilation, upregulate ER stress markers, and undergo excess apoptosis; reduced extracellular secretion of the mutant heterotrimer contributes to abnormal muscle BMs.\",\n      \"method\": \"Knock-in mouse histology/ultrastructure, immunostaining (ER stress markers, apoptosis), collagen IV secretion analysis, serum creatine kinase measurement\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knock-in model with ultrastructural, molecular and functional readouts establishing primary vascular/endothelial mechanism\",\n      \"pmids\": [\"28056338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Conditional Col4a1 mutation expressed selectively in lens cells (but not in neural crest cells alone, nor vascular endothelial cells alone on unsensitized background) causes cataracts, mild ASD, optic nerve hypoplasia, and age-related IOP dysregulation and optic nerve damage; ubiquitous expression at distinct developmental stages indicates pathogenesis occurs before E12.5 in mice.\",\n      \"method\": \"Conditional (cell-type-specific and temporally controlled) Col4a1 mutation in mice, slit-lamp biomicroscopy, OCT, IOP measurement, optic nerve histology\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional genetics with multiple cell-type-specific alleles and functional ocular readouts\",\n      \"pmids\": [\"28237965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Col4a1 mutations in mice cause progressive retinopathy driven by primary vascular defects: conditional Col4a1 mutation in vascular cells reproduces the retinal pathology (serous chorioretinopathy, hemorrhages, pathogenic angiogenesis); focal Müller cell activation and increased expression of pro-angiogenic factors were detected in Col4a1 mutant retinas.\",\n      \"method\": \"Conditional vascular-specific Col4a1 mutation, fluorescein angiography, funduscopy, OCT, electroretinography, ultrastructural analysis, Müller cell and angiogenic factor immunostaining\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional genetics with multiple functional and molecular readouts establishing primary vascular mechanism\",\n      \"pmids\": [\"26813606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Col4a1 mutant mice develop progressive neuromuscular pathology with mechanistic heterogeneity across tissues: independent muscular, neural, and vascular insults all contribute to neuromyopathy; a therapeutic strategy promoting [α1(IV)]2α2(IV) secretion can either ameliorate or exacerbate myopathy depending on the specific mutation, demonstrating mutation-dependent therapeutic responses.\",\n      \"method\": \"Col4a1 mutant mouse characterization, histology, molecular pathway analysis, pharmacological secretion-promoting treatment with phenotypic readout\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods, mutation-dependent therapeutic outcome establishes allelic mechanistic heterogeneity\",\n      \"pmids\": [\"31051113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"4-Phenylbutyric acid (PBA) treatment of Col4a1 mutant mice reduces ER stress, increases collagen IV incorporation into basement membranes, and reduces adult intracerebral hemorrhage in both preventive and therapeutic settings; however, PBA does not improve eye or kidney defects, and persistence of structural BM defects indicates that BM matrix integrity is not fully restored—establishing tissue-specific outcomes of targeting ER stress.\",\n      \"method\": \"Oral PBA treatment of mutant mice (preventive and therapeutic), ICH quantification, ER stress markers, collagen IV BM incorporation assay, mechanical stress testing of BM, kidney/eye phenotyping\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacological intervention with multiple orthogonal outcome measures and tissue-specific resolution\",\n      \"pmids\": [\"30351356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In Col4a1 p.G498V mutant mice, microhaemorrhages are associated with transient generalized blood-brain barrier permeability at the capillary level, while macrohaemorrhages originate from deep brain arteries with focal loss of smooth muscle cells via apoptosis-mediated degeneration; the same smooth muscle cell loss occurs in retinal arteries, and retinal arterial lesion load correlates strongly with macrohaemorrhage burden.\",\n      \"method\": \"Histology, immunohistochemistry, electron microscopy of brain/retinal vessels, blood-brain barrier permeability assay, time-course analysis, in-parallel retinal and brain hemorrhage quantification\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods identifying two mechanistically distinct hemorrhage processes\",\n      \"pmids\": [\"29266233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A genetic modifier screen in Col4a1 mutant mice identified a single locus (MoGS1) on Chromosome 1 containing Fn1 (fibronectin 1) that suppresses ocular anterior segment dysgenesis and myopathy (but not ICH) in Col4a1 mutants; the MoGS1 locus increases Fn1 expression and is associated with increased integrin-linked kinase levels and focal adhesion kinase phosphorylation, implicating integrin signaling in ocular and muscular COL4A1 pathology.\",\n      \"method\": \"Genetic modifier screen, QTL mapping, molecular expression analysis (Fn1, ILK, FAK phosphorylation), phenotypic scoring of ASD and myopathy\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic modifier locus with molecular correlates, single lab\",\n      \"pmids\": [\"34424299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TGFβ signaling is elevated in anterior segments from Col4a1 mutant mice; genetically reducing TGFβ signaling partially prevents ASD; TGFβ1 and TGFβ2 play distinct roles in ocular defects; pharmacologically promoting type IV collagen secretion or reducing TGFβ signaling ameliorates ocular pathology.\",\n      \"method\": \"Histology, TGFβ signaling pathway analysis, genetic reduction of TGFβ (epistasis), pharmacological treatment (secretion promoter, TGFβ inhibitor), slit-lamp phenotyping\",\n      \"journal\": \"Matrix biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis plus pharmacological rescue with multiple readouts establishing causal TGFβ pathway involvement\",\n      \"pmids\": [\"35525525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Col4a1 mutations impair sarcoplasmic reticulum (SR) Ca2+ signaling in vascular smooth muscle cells, blunting pressure-induced membrane depolarization and causing loss of myogenic vasoconstriction; this impairs autoregulation of cerebral blood flow and contributes to age-related ICH. Specifically, SR Ca2+ disruption impairs Ca2+-dependent activation of BK and TRPM4 channels. Treatment with 4-phenylbutyrate restored SR Ca2+ signaling, maintained BK and TRPM4 channel activity, preserved myogenic tone, and reduced ICH.\",\n      \"method\": \"Electrophysiology (patch clamp of SMCs), Ca2+ imaging, BK/TRPM4 channel activity assays, myogenic tone measurement, pharmacological treatment (4-PBA), ICH quantification\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro electrophysiology with pharmacological rescue and multiple orthogonal mechanistic readouts in one rigorous study\",\n      \"pmids\": [\"37963192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In a human iPSC co-culture model of COL4A1/A2 SVD, mutations induce apoptosis, migration defects, ECM remodeling, and high matrix metalloproteinase (MMP) expression in mural cells; these mural cell defects impair endothelial cell tight junctions through paracrine actions; MMP inhibition partially rescues ECM abnormalities and mural cell phenotypic changes.\",\n      \"method\": \"Human iPSC-derived mural/endothelial cell co-culture, transcriptomics, ECM analysis, MMP expression assay, pharmacological MMP inhibition, tight junction assessment\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human iPSC model with pharmacological rescue, multiple orthogonal methods\",\n      \"pmids\": [\"37977146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Fluorescently tagged COL4A1 (mTurquoise2-Col4a1 knock-in mouse) shows by FRAP that basement membrane collagen IV is extremely stable even during rapid epidermal growth; live imaging demonstrates that dividing basal cells deform but remain attached to the BM rather than losing adhesion, establishing the BM's pliability as a functional property.\",\n      \"method\": \"Fluorescent knock-in mouse (mTurq2-Col4a1), planar-sagittal live imaging, FRAP\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — FRAP and live imaging with endogenous tag; establishes COL4A1 BM stability and pliability directly\",\n      \"pmids\": [\"38051393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"At least three different nuclear proteins bind within the shared bidirectional promoter of COL4A1 and COL4A2: a CCAAT-binding protein, Sp1, and a newly identified factor 'CTCBF'; mutagenesis of binding sites showed these factors are essential for efficient transcription of both genes but with differential gene-specific effects, indicating the shared promoter functions as two overlapping gene-specific promoters with shared elements.\",\n      \"method\": \"Nuclear protein binding assays, promoter mutagenesis, transcription assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis of binding sites with transcriptional readout; single study\",\n      \"pmids\": [\"8334157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The shared promoter of COL4A1 and COL4A2 has no transcriptional activity alone; efficient transcription requires cooperative effects of downstream gene-specific activating elements; mutual inhibitory interactions between the two activating elements indicate competitive interactions with the shared promoter, explaining coordinated divergent transcription.\",\n      \"method\": \"Transient transfection with reporter constructs, deletion/mutation analyses of cis-elements, factor-binding assays\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transient transfection with systematic element dissection; single lab\",\n      \"pmids\": [\"9094419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"WT1 (Wilms tumor gene) directly transactivates the Col4a1 and Col4a2 promoters cooperatively with SOX9 in Sertoli cells; loss of Wt1 causes downregulation of Col4a1/Col4a2 mRNA and protein, leading to basement membrane breakdown and testicular cord disruption, as demonstrated by luciferase and point mutation analyses of the Col4a1 promoter.\",\n      \"method\": \"Conditional Wt1 knockout, RT-PCR, Western blot, immunostaining, luciferase reporter assay, promoter point mutagenesis\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase/mutagenesis combined with KO phenotype; single lab\",\n      \"pmids\": [\"23325811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TGFβ1 stimulation of human vascular smooth muscle cells increases COL4A1 and COL4A2 mRNA and protein expression through SMAD3- and SMAD4-dependent canonical signaling; pharmacological inhibition of ALK5 (TGFβ receptor) or siRNA knockdown of SMAD3/SMAD4 (but not SMAD2) abolishes this induction; SMAD3 overexpression alone or TGFβ1 treatment does not alter COL4A1/COL4A2 promoter activity in luciferase assays, indicating more complex regulation beyond direct promoter binding.\",\n      \"method\": \"ALK5 inhibitor treatment, siRNA knockdown of SMAD2/3/4 in human aortic SMCs, RT-PCR, protein expression, luciferase reporter assay\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal knockdown and pharmacological approaches, primary human cells; single lab\",\n      \"pmids\": [\"26310581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"COL4A1 facilitates proliferation, migration and invasion of hepatocellular carcinoma cells through activation of FAK-Src signaling; COL4A1 expression is upregulated by transcription factor RUNX1; HCC cells with high COL4A1 expression are sensitive to FAK or Src inhibitor treatment.\",\n      \"method\": \"siRNA knockdown, western blot for FAK-Src pathway activation, RUNX1 overexpression/knockdown, FAK/Src inhibitor treatment, proliferation and migration assays\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays with pathway inhibitors and upstream regulator identification; single lab\",\n      \"pmids\": [\"32746865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In Drosophila, col4a1 mutations have a strong antimorphic (dominant-negative) effect likely due to incorporation of mutant protein into the triple helix; col4a1 mutants display severe myopathy with centronuclear myofibers in oviduct muscle and ultrastructural A/I band disruption in larval body wall muscles; expression of a col4a1 transgene partially rescues dominant and recessive col4a1 mutant alleles but not col4a2 mutations.\",\n      \"method\": \"Complementation analysis of allelic series, transgene rescue, immunohistochemistry, electron microscopy of muscle ultrastructure\",\n      \"journal\": \"Matrix biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic genetic complementation + ultrastructural analysis in Drosophila ortholog model\",\n      \"pmids\": [\"22037604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HTLV-1 oncoprotein Tax is sufficient to induce COL4A1 and COL4A2 transcripts in T-cells; continuous Tax expression is required for robust COL4A1/COL4A2 protein induction; Tax activates the COL4A2 and, to a lesser extent, COL4A1 promoter in luciferase assays; COL4A2 knockout in chronically infected T-cells impairs Gag transfer between T-cells but not release of virus-like particles, linking the Tax-COL4A1/A2 axis to viral biofilm formation and transmission.\",\n      \"method\": \"Transient Tax expression, siRNA/CRISPR knockout, luciferase promoter assay, co-localization imaging (COL4/Gag), virus transfer assay\",\n      \"journal\": \"Frontiers in microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase, KO functional assay, imaging; single lab\",\n      \"pmids\": [\"31708905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"COL4A1 binds to nidogen-1 (NID1) in oral squamous cell carcinoma cells as shown by co-immunoprecipitation; NID1 overexpression reverses the inhibitory effects of COL4A1 knockdown on cell proliferation, migration, invasion, and EMT progression, establishing COL4A1–NID1 interaction as a functional axis promoting OSCC malignancy.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, NID1 overexpression rescue, proliferation/migration/invasion assays, EMT marker western blot\",\n      \"journal\": \"Experimental and therapeutic medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP binding plus rescue experiment; single lab, cancer cell line model\",\n      \"pmids\": [\"37006878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A specific COL4A1–ITGB1 interaction is highly enriched in tumorous EMT-type urothelial cells and endothelial cells; targeting COL4A1–ITGB1 with specific antibodies significantly suppresses tumorous angiogenesis and alleviates gemcitabine resistance in urothelial carcinoma.\",\n      \"method\": \"Single-cell RNA sequencing, ligand-receptor interaction analysis, antibody blockade functional assay (angiogenesis, drug resistance)\",\n      \"journal\": \"Drug resistance updates\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — receptor-ligand interaction supported by functional antibody blockade; single study\",\n      \"pmids\": [\"38968684\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"COL4A1 encodes the α1 chain of type IV collagen that obligatorily heterotrimer­izes with COL4A2 to form [α1(IV)]₂α2(IV), a fundamental scaffold of nearly all basement membranes; disease-causing mutations—most commonly glycine substitutions in the Gly-X-Y collagen repeat—impair folding and secretion of the heterotrimer, causing its intracellular accumulation in the ER, activation of ER/sarcoplasmic reticulum stress and the unfolded protein response, structural basement membrane deficits, and dysregulation of downstream signaling (TGFβ, integrin/FAK/ILK, NOS/NO, SR Ca²⁺/BK/TRPM4 channels); alternatively, haploinsufficiency or 3'UTR mutations that derepress miR-29-mediated suppression cause COL4A1 overexpression; collectively these mechanisms underlie a multisystem dominant disorder (Gould syndrome) affecting cerebral vasculature, eyes, kidneys, and skeletal muscle, with allelic and tissue-specific mechanistic heterogeneity determining the variable clinical expressivity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"COL4A1 encodes the α1 chain of type IV collagen, a core structural component of basement membranes that obligatorily assembles with COL4A2 into an [α1(IV)]₂α2(IV) heterotrimer; mutations in either chain impair secretion of the entire heterotrimer, establishing their physical and functional interdependence [#4]. The dominant pathogenic mechanism is dominant-negative: glycine substitutions and other mutations in the Gly-X-Y collagen repeat block secretion of both mutant and normal chains, causing intracellular retention, ER stress and activation of the unfolded protein response, alongside structural deficits in vascular, ocular, renal and muscle basement membranes [#0, #1, #2, #3]. Distinct genetic mechanisms also operate: nonsense-mediated decay of truncating alleles produces haploinsufficiency [#6], while 3'UTR mutations that disrupt a miR-29 binding site derepress COL4A1 and cause gain-of-expression cerebral small vessel disease [#12]. Downstream of basement membrane disruption, COL4A1 mutations dysregulate multiple signaling axes — elevated TGFβ signaling drives anterior segment dysgenesis [#20], integrin/ILK/FAK signaling (modulated by fibronectin) contributes to ocular and muscular pathology [#19], reduced NOS activity produces vascular dysfunction [#3], and impaired sarcoplasmic reticulum Ca²⁺ signaling blunts BK/TRPM4 channel activity and myogenic tone in cerebral vascular smooth muscle [#21]. Pathology arises through cell-type-specific routes, with endothelial and mural cell defects driving myopathy, retinopathy and hemorrhage [#13, #15, #18, #22]. Collectively these mechanisms underlie a dominant multisystem disorder affecting cerebral vasculature, eyes, kidneys and skeletal muscle, with the folding/secretion defect being pharmacologically targetable by chemical chaperones such as 4-phenylbutyrate, though with tissue- and allele-specific outcomes [#8, #16, #17, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established that a Col4a1 mutation acts dominantly by inhibiting secretion of both mutant and normal type IV collagen, linking the gene to vascular basement membrane integrity and cerebral hemorrhage and revealing an environmental (trauma) trigger.\",\n      \"evidence\": \"Semidominant mouse mutant characterization with cellular secretion assay, vascular BM histology, and surgical delivery intervention\",\n      \"pmids\": [\"15905400\", \"16598045\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the molecular folding defect at residue level\", \"Mechanism of trauma sensitization not defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed that conserved glycine substitutions in the Gly-X-Y repeat exert dominant-negative effects and that allele position predicts phenotype severity, defining genotype-severity correlations across tissues.\",\n      \"evidence\": \"ENU mutagenesis allelic series in mice with histology, EM, and ophthalmological phenotyping\",\n      \"pmids\": [\"16159887\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of milder Yaa-residue allele not biochemically dissected\", \"Did not address signaling consequences\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Connected non-secretion to intracellular accumulation and ER stress, and showed genetic context (a dominant modifier) can rescue ocular phenotypes, indicating modifiable downstream pathology.\",\n      \"evidence\": \"Mouse genetics with secretion assay, ER stress markers, and genetic modifier mapping\",\n      \"pmids\": [\"17317786\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the modifier locus not defined here\", \"Causal chain from ER stress to tissue dysgenesis incomplete\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Mapped HANAC-associated mutations to the integrin-binding CB3[IV] region, implicating altered cell–collagen IV interactions in systemic vascular defects.\",\n      \"evidence\": \"Clinical/genetic characterization with mutation mapping to the integrin-binding domain across families\",\n      \"pmids\": [\"18160688\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct integrin-binding functional assay not reported\", \"Causality of altered integrin engagement not experimentally tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated that mutations produce vascular dysfunction through both structural BM defects and ER stress, including reduced NOS activity and blood pressure abnormalities, broadening the mechanism beyond pure structural failure.\",\n      \"evidence\": \"Vascular function assays, NOS inhibitor pharmacology, collagen IV imaging, blood pressure and RBC measurement, UPR markers in Col4a1+/Raw mice\",\n      \"pmids\": [\"20056676\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Link between BM defect and reduced NOS activity not mechanistically resolved\", \"RBC volume reduction mechanism unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Proved COL4A1 and COL4A2 form an obligate heterotrimer whose secretion fails when either chain is mutated, unifying the two genes' disease mechanisms.\",\n      \"evidence\": \"Reciprocal cellular secretion/ER retention assays, UPR markers, and Col4a2 mutant mouse phenotyping with ICH patient sequencing\",\n      \"pmids\": [\"22209247\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry/assembly kinetics not detailed\", \"Tissue-specific differences in heterotrimer handling not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Distinguished COL4A1 myopathy/ocular pathology from dystroglycanopathies by showing dystroglycan glycosylation is unaltered, defining a mechanistically distinct disease route.\",\n      \"evidence\": \"Mouse histology, secretion assay, and dystroglycan immunoblot/glycosylation analysis with patient mutation identification\",\n      \"pmids\": [\"21625620\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of neuronal localization defect not defined\", \"How BM defect translates to MEB/WWS-like features unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified haploinsufficiency via nonsense-mediated decay as a pathogenic mechanism distinct from dominant-negative missense effects.\",\n      \"evidence\": \"NMD assay in patient fibroblasts, protein quantification, RT-PCR splice analysis, skin EM\",\n      \"pmids\": [\"23065703\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why loss-of-function and dominant-negative converge on similar disease not explained\", \"Tissue threshold for haploinsufficiency unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Extended the biosynthetic secretion defect to sporadic ICH variants, indicating a shared mechanism across familial and sporadic cerebrovascular disease.\",\n      \"evidence\": \"Cellular biosynthesis/secretion assay comparing patient vs control variants\",\n      \"pmids\": [\"22522439\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Only two variants tested in a single lab\", \"No in vivo confirmation of these specific variants\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Confirmed ER folding/secretion as a targetable mechanism by showing reduced temperature or 4-phenylbutyrate ameliorates biosynthetic defects, while documenting allele-specific biosynthetic signatures.\",\n      \"evidence\": \"Biosynthesis assays across allelic series primary cells with pharmacological/temperature rescue\",\n      \"pmids\": [\"24203695\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Allele-specific signatures not mechanistically explained\", \"In vivo efficacy not established in this study\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified WT1, cooperating with SOX9, as a direct transcriptional activator of Col4a1/Col4a2, linking gene expression control to basement membrane maintenance in Sertoli cells.\",\n      \"evidence\": \"Conditional Wt1 knockout with RT-PCR, Western blot, immunostaining, and luciferase promoter mutagenesis\",\n      \"pmids\": [\"23325811\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generalizability beyond Sertoli cells untested\", \"Direct WT1 binding site occupancy in vivo not shown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined a developmental role for the heterotrimer in glomerular basement membrane formation and linked Bowman's capsule defects to metalloproteinase induction and activated parietal epithelial cells expressing ILK and DDR1.\",\n      \"evidence\": \"G498V knock-in mouse with histology, MMP analysis, and functional renal assays\",\n      \"pmids\": [\"26260163\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trigger linking BM defect to MMP induction unclear\", \"Cell-intrinsic vs paracrine contributions not separated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed TGFβ1 induces COL4A1/COL4A2 expression in vascular SMCs via SMAD3/SMAD4-dependent canonical signaling, identifying an upstream cytokine regulator with regulation beyond direct promoter binding.\",\n      \"evidence\": \"ALK5 inhibitor, SMAD2/3/4 siRNA, RT-PCR, protein and luciferase assays in human aortic SMCs\",\n      \"pmids\": [\"26310581\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of induction independent of direct promoter activity not resolved\", \"Single lab, one cell type\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated cell-type-dependent renal mechanisms — structural BM defects driving glomerular filtration impairment versus chronic ER stress driving medullary atrophy — and a BM role in tubular aldosterone responsiveness.\",\n      \"evidence\": \"Mutant mouse phenotyping with ER stress markers, EM of BMs, and functional renal assays\",\n      \"pmids\": [\"26839400\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why ER stress predominates in medulla without tubular BM defects unclear\", \"Molecular basis of aldosterone resistance not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established a primary vascular basis for progressive retinopathy by reproducing pathology with vascular-cell-specific mutation, accompanied by Müller cell activation and pro-angiogenic factor upregulation.\",\n      \"evidence\": \"Conditional vascular Col4a1 mutation with angiography, OCT, ERG, ultrastructure, and immunostaining\",\n      \"pmids\": [\"26813606\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of pro-angiogenic signal not specified\", \"Müller cell activation cause vs consequence unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Discovered a gain-of-expression mechanism whereby disruption of a miR-29 3'UTR binding site upregulates COL4A1 and causes ischemic cerebral small vessel disease (PADMAL).\",\n      \"evidence\": \"Luciferase reporter, RT-qPCR in patient fibroblasts, and linkage/mutation screening\",\n      \"pmids\": [\"27666438\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How COL4A1 overexpression causes ischemic pathology mechanistically unknown\", \"Tissue specificity of miR-29 derepression not addressed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified endothelial cells in muscle capillaries as the primary driver of HANAC myopathy through intracellular mutant heterotrimer accumulation, ER stress, and apoptosis.\",\n      \"evidence\": \"G498V knock-in ultrastructure, ER stress/apoptosis immunostaining, secretion analysis, and serum CK\",\n      \"pmids\": [\"28056338\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution of muscle-intrinsic defects not fully separated\", \"Apoptotic trigger downstream of ER stress not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Used conditional and temporally controlled mutation to localize ocular pathogenesis to lens cells and to an early developmental window (before E12.5).\",\n      \"evidence\": \"Cell-type-specific and temporal Col4a1 mutation with slit-lamp, OCT, IOP, and optic nerve histology\",\n      \"pmids\": [\"28237965\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which lens cell BM defect causes IOP dysregulation unclear\", \"Later-stage contributions to optic nerve damage not isolated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved two mechanistically distinct hemorrhage processes — capillary-level BBB permeability driving microhemorrhages and apoptotic smooth muscle cell loss in deep arteries driving macrohemorrhages — with retinal arterial lesions as a correlated biomarker.\",\n      \"evidence\": \"Histology, IHC, EM of brain/retinal vessels, BBB permeability assay, and parallel hemorrhage quantification in G498V mice\",\n      \"pmids\": [\"29266233\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trigger of smooth muscle cell apoptosis not defined\", \"Temporal relationship between micro- and macrohemorrhage unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated tissue-level mechanistic heterogeneity in neuromuscular disease and that secretion-promoting therapy can ameliorate or worsen myopathy depending on the mutation, establishing allele-dependent therapeutic responses.\",\n      \"evidence\": \"Mutant mouse characterization with histology, pathway analysis, and pharmacological secretion-promoting treatment\",\n      \"pmids\": [\"31051113\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of opposite therapeutic outcomes per allele unclear\", \"Relative weight of muscular vs neural vs vascular insults not quantified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed 4-phenylbutyrate reduces ER stress and intracerebral hemorrhage in vivo but fails to correct eye/kidney defects or fully restore BM structure, defining tissue-specific limits of ER-stress-targeted therapy.\",\n      \"evidence\": \"Oral PBA treatment (preventive/therapeutic) with ICH quantification, ER stress markers, BM incorporation, and mechanical stress testing\",\n      \"pmids\": [\"30351356\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why eye/kidney are PBA-refractory unexplained\", \"Residual structural BM defect not addressed by chaperone therapy\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed the HTLV-1 oncoprotein Tax induces COL4A1/COL4A2, linking the gene to viral biofilm-mediated cell-to-cell Gag transfer.\",\n      \"evidence\": \"Tax expression, CRISPR/siRNA knockout, luciferase promoter assays, colocalization imaging, and virus transfer assays in T-cells\",\n      \"pmids\": [\"31708905\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"COL4A1-specific (vs COL4A2) contribution to transfer not isolated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified a pro-tumorigenic role for COL4A1 in hepatocellular carcinoma via FAK-Src signaling activation, downstream of RUNX1 transcriptional control, defining a druggable axis.\",\n      \"evidence\": \"siRNA knockdown, FAK-Src Western blots, RUNX1 manipulation, FAK/Src inhibitors, and proliferation/migration assays\",\n      \"pmids\": [\"32746865\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether secreted vs intracellular COL4A1 drives signaling unclear\", \"Single lab, cell-line based\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified a single modifier locus containing Fn1 that suppresses ocular and muscular (but not cerebral) phenotypes and correlates with increased ILK and FAK phosphorylation, implicating integrin signaling in tissue-specific pathology.\",\n      \"evidence\": \"Genetic modifier screen, QTL mapping, and molecular expression analysis (Fn1, ILK, pFAK)\",\n      \"pmids\": [\"34424299\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct causal proof that Fn1 is the modifier gene incomplete\", \"Why ICH is not suppressed unexplained\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified a direct COL4A1–NID1 (nidogen-1) interaction promoting OSCC malignancy, with NID1 overexpression rescuing knockdown phenotypes.\",\n      \"evidence\": \"Co-immunoprecipitation, siRNA knockdown, NID1 rescue, and proliferation/migration/invasion/EMT assays\",\n      \"pmids\": [\"37006878\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single Co-IP in one cancer cell line without reciprocal validation\", \"Physiological relevance outside cancer untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established TGFβ signaling as a causal driver of ocular anterior segment dysgenesis downstream of COL4A1 mutation, with distinct TGFβ1/TGFβ2 roles and rescue by either secretion-promotion or TGFβ inhibition.\",\n      \"evidence\": \"Histology, TGFβ pathway analysis, genetic epistasis, and pharmacological treatment with slit-lamp phenotyping\",\n      \"pmids\": [\"35525525\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking BM defect to elevated TGFβ not defined\", \"Whether TGFβ axis operates in non-ocular tissues unaddressed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined a signaling mechanism for cerebral hemorrhage: impaired sarcoplasmic reticulum Ca²⁺ signaling blunts BK/TRPM4 channel activation and myogenic vasoconstriction, disrupting cerebral autoregulation, with 4-PBA restoring function.\",\n      \"evidence\": \"Patch-clamp electrophysiology, Ca²⁺ imaging, BK/TRPM4 channel assays, myogenic tone, and PBA rescue with ICH quantification\",\n      \"pmids\": [\"37963192\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BM/ER defect mechanistically disrupts SR Ca²⁺ handling unresolved\", \"Generalizability across alleles untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established in a human iPSC co-culture model that mutant mural cells exhibit apoptosis, ECM remodeling and high MMP expression that paracrine-impair endothelial tight junctions, with MMP inhibition partially rescuing.\",\n      \"evidence\": \"iPSC-derived mural/endothelial co-culture, transcriptomics, ECM/MMP analysis, MMP inhibition, and tight junction assessment\",\n      \"pmids\": [\"37977146\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of paracrine factor(s) not defined\", \"Incomplete rescue indicates additional MMP-independent mechanisms\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated by endogenous fluorescent tagging that basement membrane collagen IV is extremely stable yet pliable, allowing basal cells to deform without detaching during epidermal growth, establishing a functional biomechanical property.\",\n      \"evidence\": \"mTurquoise2-Col4a1 knock-in mouse, planar-sagittal live imaging, and FRAP\",\n      \"pmids\": [\"38051393\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of BM pliability not dissected\", \"How disease mutations alter this property untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified a COL4A1–ITGB1 ligand-receptor interaction enriched in tumor EMT-type and endothelial cells whose antibody blockade suppresses angiogenesis and reverses gemcitabine resistance.\",\n      \"evidence\": \"Single-cell RNA-seq, ligand-receptor analysis, and antibody blockade functional assays in urothelial carcinoma\",\n      \"pmids\": [\"38968684\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical COL4A1-ITGB1 binding not validated\", \"Single study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the upstream structural/ER-stress defect mechanistically connects to the diverse downstream signaling derangements (TGFβ elevation, integrin/ILK/FAK activation, SR Ca²⁺ and BK/TRPM4 disruption, NOS reduction) — and why these couplings and therapeutic responses are tissue- and allele-specific — remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unifying molecular link from BM/ER defect to each signaling axis\", \"Allele-specific therapeutic divergence mechanistically unexplained\", \"Tissue-specificity of refractoriness to chaperone therapy not understood\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 1, 4, 23]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [9, 32]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0030312\", \"supporting_discovery_ids\": [0, 1, 4, 10, 23]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [2, 3, 4, 13]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [8, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [0, 4, 10, 23]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [2, 3, 4, 13]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 6, 12, 18]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [20, 21, 28]}\n    ],\n    \"complexes\": [\"[α1(IV)]₂α2(IV) type IV collagen heterotrimer\"],\n    \"partners\": [\"COL4A2\", \"NID1\", \"ITGB1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}